

Please type a plus sign (+) inside this box ☐

11-01-00

PTO/SB/05 (4/98)

Approved for use through 09/30/2000. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53 (b))

Attorney Docket No. LEX-0081-USA

First Inventor or Application Identifier Marie Harras et al.

Title Novel Human Transporter Proteins and Polynucleotide Encoding the Same

Express Mail label No. EL672756229US

PTO  
10/31/00  
1996 509 708 0253

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO:

Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1 ☐ \*Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)

2 ☒ Specification (Total Pages (Preferred arrangement set forth below) 25)

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the disclosure

3 ☐ Drawing(s) (35 U.S.C. 113) (Total Sheets)

4 Oath or Declaration (Total 1)

a. ☒ Newly unexecuted (original or copy)

b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 16 completed)

i ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

NOTE FOR FEES 1 & 15 IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.29) EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS REIED UPON (37 C.F.R. § 1.26)

5. ☐ Microfiche Computer Program (Appendix)

6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

a. ☐ Computer Readable Copy

b. ☒ Paper Copy (identical to computer copy)

c. ☐ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment Papers (cover sheet & document(s))

8. ☐ 37 C.F.R. § 79(b) Statement (when there is an assignee) ☐ Power of Attorney

9. ☐ English Translation Document (if applicable)

10. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations

11. ☐ Preliminary Amendment

12. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)

13. ☒ Small Entity Statement ☐ Statement filed in prior application, Status still proper and desired (PTO/B02-12)

14. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)

15. ☐ Other: .....

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional

☐ Continuation-in-part (CIP) of prior application No. ....

Prior application Information: Examiner .....

Group/Art Unit: .....

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

## 17. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label



or ☐ Correspondence address below

Name

24231

PATENT TRADEMARK OFFICE

Address

City

State

Zip Code

Country

Telephone

(281) 362-6554

Fax

(281) 364-0155

Name (Print/Type)

Lance K. Ishimoto

Registration No.

41866

Signature

*Lance K. Ishimoto*

Date

October 31, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

**STATEMENT CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) & 1.27(c)) -- SMALL BUSINESS CONCERN**

Docket Number (Optional)  
**LEX-0081-USA**

Applicant, Patentee, or Identifier: Marie Harras et al.

Application or Patent No.: \_\_\_\_\_

Filed or Issued: October 31, 2000

Title: Novel Human Transporter Proteins and Polynucleotides Encoding the Same

I hereby state that I am

- ☐ the owner of the small business concern identified below;  
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN Lexicon Genetics Incorporated

ADDRESS OF SMALL BUSINESS CONCERN 4000 Research Forest Drive, The Woodlands, TX 77381

I hereby state that the above identified small business concern qualifies as a small business concern as defined in 13 CFR Part 121 for purposes of paying reduced fees to the United States Patent and Trademark Office. Questions related to size standards for a small business concern may be directed to: Small Business Administration, Size Standards Staff, 409 Third Street, SW, Washington, DC 20416.

I hereby state that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

- ☒ the specification filed herewith with title as listed above.  
☐ the application identified above.  
☐ the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern, or organization having rights in the invention must file separate statements as to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization having any rights in the invention is listed below:

- ☒ No such persons, concerns, or organizations exist.  
☐ Each such person, concern, or organization is listed below:

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

NAME OF PERSON SIGNING Lance K. Ishimoto

TITLE OF PERSON IF OTHER THAN OWNER Vice President - Intellectual Property

ADDRESS OF PERSON SIGNING 4000 Research Forest Drive, The Woodlands, TX 77381

SIGNATURE 

Reg. No. 41,866

DATE October 31, 2000

**NOVEL HUMAN TRANSPORTER PROTEINS AND  
POLYNUCLEOTIDES ENCODING THE SAME**

5           The present application claims the benefit of U.S.  
Provisional Application Number 60/163,018 which was filed on  
November 2, 1999 and is herein incorporated by reference in its  
entirety.

1. INTRODUCTION

10           The present invention relates to the discovery,  
identification, and characterization of novel human  
polynucleotides encoding proteins that share sequence similarity  
with mammalian transporter proteins. The invention encompasses  
the described polynucleotides, host cell expression systems, the  
15   encoded proteins, fusion proteins, polypeptides and peptides,  
antibodies to the encoded proteins and peptides, and genetically  
engineered animals that either lack or over express the disclosed  
genes, antagonists and agonists of the proteins, and other  
compounds that modulate the expression or activity of the proteins  
20   encoded by the disclosed genes that can be used for diagnosis,  
drug screening, clinical trial monitoring, the treatment of  
diseases and disorders, or otherwise contributing to the quality  
of life.

2. BACKGROUND OF THE INVENTION

25           Transporter proteins are integral membrane proteins that  
mediate or facilitate the passage of materials across the lipid  
bilayer. Given that the transport of materials across the  
membrane can play an important physiological role, transporter  
proteins are good drug targets. Additionally, one of the  
30   mechanisms of drug resistance involves diseased cells using  
cellular transporter systems to export chemotherapeutic agents  
from the cell. Such mechanisms are particularly relevant to cells  
manifesting resistance to a multiplicity of drugs.

### 3. SUMMARY OF THE INVENTION

The present invention relates to the discovery, identification, and characterization of nucleotides that encode novel human proteins, and the corresponding amino acid sequences of these proteins. The novel human proteins (NHPs) described for the first time herein share structural similarity with mammalian multi-drug resistance (MDR) proteins and cellular transporters.

The novel human nucleic acid sequences described herein, encode alternative proteins/open reading frames (ORFs) of 659, 705, 1,063, 496, 542, 900, 978, 1,024, 1,382, 815, 861, 1,219, and amino acids in length (see SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 respectively).

The invention also encompasses agonists and antagonists of the described NHPs, including small molecules, large molecules, mutant NHPs, or portions thereof that compete with native NHP, peptides, and antibodies, as well as nucleotide sequences that can be used to inhibit the expression of the described NHPs (e.g., antisense and ribozyme molecules, and gene or regulatory sequence replacement constructs) or to enhance the expression of the described NHP genes (e.g., expression constructs that place the described gene under the control of a strong promoter system), and transgenic animals that express a NHP transgene, or "knock-outs" (which can be conditional) that do not express a functional NHP. A knockout ES cell line has been produced that contains a gene trap mutation in the murine ortholog of the described gene.

Further, the present invention also relates to processes for identifying compounds that modulate, i.e., act as agonists or antagonists, of NHP expression and/or NHP activity that utilize purified preparations of the described NHPs and/or NHP product, or cells expressing the same. Such compounds can be used as therapeutic agents for the treatment of any of a wide variety of symptoms associated with biological disorders or imbalances.

#### 4. DESCRIPTION OF THE SEQUENCE LISTING AND FIGURES

The Sequence Listing provides the sequences of the described NHP ORFs that encode the described NHP amino acid sequences. SEQ ID NO:25 describes a NHP ORF as well as flanking 5' and 3'

5 sequences.

#### 5. DETAILED DESCRIPTION OF THE INVENTION

The NHPs, described for the first time herein, are novel proteins that are expressed in, *inter alia*, human cell lines, predominantly in human mammary gland, as well as human fetal liver, prostate, testis, and gene trapped human cells.

The present invention encompasses the nucleotides presented in the Sequence Listing, host cells expressing such nucleotides, the expression products of such nucleotides, and: (a) nucleotides that encode mammalian homologs of the described genes, including the specifically described NHPs, and the NHP products; (b) nucleotides that encode one or more portions of the NHPs that correspond to functional domains, and the polypeptide products specified by such nucleotide sequences, including but not limited to the novel regions of any active domain(s); (c) isolated nucleotides that encode mutant versions, engineered or naturally occurring, of the described NHPs in which all or a part of at least one domain is deleted or altered, and the polypeptide products specified by such nucleotide sequences, including but not limited to soluble proteins and peptides in which all or a portion of the signal sequence is deleted; (d) nucleotides that encode chimeric fusion proteins containing all or a portion of a coding region of an NHP, or one of its domains (e.g., a receptor or ligand binding domain, accessory protein/self-association domain, etc.) fused to another peptide or polypeptide; or (e) therapeutic or diagnostic derivatives of the described polynucleotides such as oligonucleotides, antisense polynucleotides, ribozymes, dsRNA, or gene therapy constructs comprising a sequence first disclosed in

the Sequence Listing. As discussed above, the present invention includes: (a) the human DNA sequences presented in the Sequence Listing (and vectors comprising the same) and additionally contemplates any nucleotide sequence encoding a contiguous NHP open reading frame (ORF) that hybridizes to a complement of a DNA sequence presented in the Sequence Listing under highly stringent conditions, *e.g.*, hybridization to filter-bound DNA in 0.5 M NaHPO<sub>4</sub>, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel F.M. *et al.*, eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3) and encodes a functionally equivalent gene product. Additionally contemplated are any nucleotide sequences that hybridize to the complement of a DNA sequence that encodes and expresses an amino acid sequence presented in the Sequence Listing under moderately stringent conditions, *e.g.*, washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel *et al.*, 1989, *supra*), yet still encodes a functionally equivalent NHP product. Functional equivalents of a NHP include naturally occurring NHPs present in other species and mutant NHPs whether naturally occurring or engineered (by site directed mutagenesis, gene shuffling, directed evolution as described in, for example, U.S. Patent No. 5,837,458). The invention also includes degenerate nucleic acid variants of the disclosed NHP polynucleotide sequences.

Additionally contemplated are polynucleotides encoding NHP ORFs, or their functional equivalents, encoded by polynucleotide sequences that are about 99, 95, 90, or about 85 percent similar or identical to corresponding regions of the nucleotide sequences of the Sequence Listing (as measured by BLAST sequence comparison analysis using, for example, the GCG sequence analysis package using standard default settings).

The invention also includes nucleic acid molecules, preferably DNA molecules, that hybridize to, and are therefore the complements of, the described NHP gene nucleotide sequences. Such hybridization conditions may be highly stringent or less highly  
5 stringent, as described above. In instances where the nucleic acid molecules are deoxyoligonucleotides ("DNA oligos"), such molecules are generally about 16 to about 100 bases long, or about 20 to about 80, or about 34 to about 45 bases long, or any variation or combination of sizes represented therein that  
10 incorporate a contiguous region of sequence first disclosed in the Sequence Listing. Such oligonucleotides can be used in conjunction with the polymerase chain reaction (PCR) to screen libraries, isolate clones, and prepare cloning and sequencing templates, etc..

15 Alternatively, such NHP oligonucleotides can be used as hybridization probes for screening libraries, and assessing gene expression patterns (particularly using a micro array or high-throughput "chip" format). Additionally, a series of the described NHP oligonucleotide sequences, or the complements  
20 thereof, can be used to represent all or a portion of the described NHP sequences. The oligonucleotides, typically between about 16 to about 40 (or any whole number within the stated range) nucleotides in length can partially overlap each other and/or the NHP sequence may be represented using oligonucleotides that do not  
25 overlap. Accordingly, the described NHP polynucleotide sequences shall typically comprise at least about two or three distinct oligonucleotide sequences of at least about 18, and preferably about 25, nucleotides in length that are each first disclosed in the described Sequence Listing. Such oligonucleotide sequences  
30 may begin at any nucleotide present within a sequence in the Sequence Listing and proceed in either a sense (5'-to-3') orientation vis-a-vis the described sequence or in an antisense orientation.

For oligonucleotide probes, highly stringent conditions may refer, e.g., to washing in 6xSSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base oligos). These nucleic

5 acid molecules may encode or act as NHP gene antisense molecules, useful, for example, in NHP gene regulation (for and/or as antisense primers in amplification reactions of NHP gene nucleic acid sequences). With respect to NHP gene regulation, such techniques can be used to regulate biological functions. Further,  
10 such sequences may be used as part of ribozyme and/or triple helix sequences that are also useful for NHP gene regulation.

Inhibitory antisense or double stranded oligonucleotides can additionally comprise at least one modified base moiety which is selected from the group including but not limited to

15 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine,  
20 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil,  
25 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.  
30

The antisense oligonucleotide can also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.



In yet another embodiment, the antisense oligonucleotide will comprise at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an  $\alpha$ -anomeric oligonucleotide. An  $\alpha$ -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other (Gautier *et al.*, 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue *et al.*, 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue *et al.*, 1987, FEBS Lett. 215:327-330).

Alternatively, double stranded RNA can be used to disrupt the expression and function of a targeted NHP.

Oligonucleotides of the invention can be synthesized by standard methods known in the art, *e.g.* by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides can be synthesized by the method of Stein *et al.* (1988, Nucl. Acids Res. 16:3209), and methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin *et al.*, 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

Low stringency conditions are well known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual (and periodic updates thereof), Cold Springs Harbor Press, N.Y.; and

Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

Alternatively, suitably labeled NHP nucleotide probes can be used to screen a human genomic library using appropriately  
5 stringent conditions or by PCR. The identification and characterization of human genomic clones is helpful for identifying polymorphisms (including, but not limited to, nucleotide repeats, microsatellite alleles, single nucleotide polymorphisms, or coding single nucleotide polymorphisms),  
10 determining the genomic structure of a given locus/allele, and designing diagnostic tests. For example, sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use in amplification assays to detect mutations within the exons, introns, splice sites (e.g.,  
15 splice acceptor and/or donor sites), etc., that can be used in diagnostics and pharmacogenomics.

Further, a NHP gene homolog can be isolated from nucleic acid from an organism of interest by performing PCR using two degenerate or "wobble" oligonucleotide primer pools designed on  
20 the basis of amino acid sequences within the NHP products disclosed herein. The template for the reaction may be total RNA, mRNA, and/or cDNA obtained by reverse transcription of mRNA prepared from human or non-human cell lines or tissue known or suspected to express an allele of a NHP gene.

25 The PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequence of the desired NHP gene. The PCR fragment can then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment can be labeled and used to screen a cDNA library, such as  
30 a bacteriophage cDNA library. Alternatively, the labeled fragment can be used to isolate genomic clones via the screening of a genomic library.

PCR technology can also be used to isolate full length cDNA sequences. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source (i.e., one known, or suspected, to express a NHP gene). A reverse transcription (RT) reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be "tailed" using a standard terminal transferase reaction, the hybrid may be digested with RNase H, and second strand synthesis may then be primed with a complementary primer. Thus, cDNA sequences upstream of the amplified fragment can be isolated. For a review of cloning strategies that can be used, see e.g., Sambrook et al., 1989, *supra*.

A cDNA encoding a mutant NHP gene can be isolated, for example, by using PCR. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying a mutant NHP allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal gene. Using these two primers, the product is then amplified via PCR, optionally cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the art. By comparing the DNA sequence of the mutant NHP allele to that of a corresponding normal NHP allele, the mutation(s) responsible for the loss or alteration of function of the mutant NHP gene product can be ascertained.

Alternatively, a genomic library can be constructed using DNA obtained from an individual suspected of or known to carry a mutant NHP allele (e.g., a person manifesting a NHP-associated phenotype such as, for example, obesity, high blood pressure,

connective tissue disorders, infertility, etc.), or a cDNA library can be constructed using RNA from a tissue known, or suspected, to express a mutant NHP allele. A normal NHP gene, or any suitable fragment thereof, can then be labeled and used as a probe to  
5 identify the corresponding mutant NHP allele in such libraries. Clones containing mutant NHP gene sequences can then be purified and subjected to sequence analysis according to methods well known to those skilled in the art.

Additionally, an expression library can be constructed  
10 utilizing cDNA synthesized from, for example, RNA isolated from a tissue known, or suspected, to express a mutant NHP allele in an individual suspected of or known to carry such a mutant allele. In this manner, gene products made by the putatively mutant tissue can be expressed and screened using standard antibody screening  
15 techniques in conjunction with antibodies raised against a normal NHP product, as described below. (For screening techniques, see, for example, Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor.)

Additionally, screening can be accomplished by screening with  
20 labeled NHP fusion proteins, such as, for example, alkaline phosphatase-NHP or NHP-alkaline phosphatase fusion proteins. In cases where a NHP mutation results in an expressed gene product with altered function (e.g., as a result of a missense or a frameshift mutation), polyclonal antibodies to a NHP are likely to  
25 cross-react with a corresponding mutant NHP gene product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis according to methods well known in the art.

The invention also encompasses (a) DNA vectors that contain  
30 any of the foregoing NHP coding sequences and/or their complements (i.e., antisense); (b) DNA expression vectors that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding

sequences (for example, baculo virus as described in U.S. Patent No. 5,869,336 herein incorporated by reference); (c) genetically engineered host cells that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that  
5 directs the expression of the coding sequences in the host cell; and (d) genetically engineered host cells that express an endogenous NHP gene under the control of an exogenously introduced regulatory element (*i.e.*, gene activation). As used herein, regulatory elements include, but are not limited to,  
10 inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the art that drive and regulate expression. Such regulatory elements include but are not limited to the human cytomegalovirus (hCMV) immediate early gene, regulatable, viral elements  
15 (particularly retroviral LTR promoters), the early or late promoters of SV40 adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase  
20 (PGK), the promoters of acid phosphatase, and the promoters of the yeast  $\alpha$ -mating factors.

The present invention also encompasses antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists and agonists of the NHP, as well as compounds or nucleotide constructs  
25 that inhibit expression of a NHP gene (transcription factor inhibitors, antisense and ribozyme molecules, or gene or regulatory sequence replacement constructs), or promote the expression of a NHP (*e.g.*, expression constructs in which NHP coding sequences are operatively associated with expression  
30 control elements such as promoters, promoter/enhancers, etc.).

The NHPs or NHP peptides, NHP fusion proteins, NHP nucleotide sequences, antibodies, antagonists and agonists can be useful for the detection of mutant NHPs or inappropriately expressed NHPs for

the diagnosis of disease. The NHP proteins or peptides, NHP fusion proteins, NHP nucleotide sequences, host cell expression systems, antibodies, antagonists, agonists and genetically engineered cells and animals can be used for screening for drugs (or high throughput screening of combinatorial libraries) effective in the treatment of the symptomatic or phenotypic manifestations of perturbing the normal function of NHP in the body. The use of engineered host cells and/or animals may offer an advantage in that such systems allow not only for the identification of compounds that bind to the endogenous receptor for an NHP, but can also identify compounds that trigger NHP-mediated activities or pathways.

Finally, the NHP products can be used as therapeutics. For example, soluble derivatives such as NHP peptides/domains corresponding the NHPs, NHP fusion protein products (especially NHP-Ig fusion proteins, i.e., fusions of a NHP, or a domain of a NHP, to an IgFc), NHP antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists or agonists (including compounds that modulate or act on downstream targets in a NHP-mediated pathway) can be used to directly treat diseases or disorders. For instance, the administration of an effective amount of soluble NHP, or a NHP-IgFc fusion protein or an anti-idiotypic antibody (or its Fab) that mimics the NHP could activate or effectively antagonize the endogenous NHP receptor. Nucleotide constructs encoding such NHP products can be used to genetically engineer host cells to express such products *in vivo*; these genetically engineered cells function as "bioreactors" in the body delivering a continuous supply of a NHP, a NHP peptide, or a NHP fusion protein to the body. Nucleotide constructs encoding functional NHPs, mutant NHPs, as well as antisense and ribozyme molecules can also be used in "gene therapy" approaches for the modulation of NHP expression. Thus, the invention also

encompasses pharmaceutical formulations and methods for treating biological disorders.

Various aspects of the invention are described in greater detail in the subsections below.

5

## 5.1 THE NHP SEQUENCES

The cDNA sequences and the corresponding deduced amino acid sequences of the described NHPs are presented in the Sequence Listing. The NHP nucleotides were obtained from clustered human  
10 gene trapped sequences, ESTs, and human testis and mammary gland cDNA libraries (Edge Biosystems, Gaithersburg, MD). The described sequences can also incorporate several coding region single nucleotide polymorphisms (cSNPs). The first polymorphism is a A to G transition at position 704 of, for example, SED ID NO: 23,  
15 which results in a corresponding change of gln to an arg at, for example, position 235 of SEQ ID NO:24; the second can occur at position 2184 of, for example, SEQ ID NO:23 that changes a gln to a his at position 728 of, for example, SEQ ID NO:24; and the third cSNP involves a silent T to C transition at position 2,436 of, for  
20 example, SEQ ID NO:23.

Similar MDR encoding sequences, uses, and applications that are germane to the described NHPs, are described in U.S. Patents Nos. 5,198,344 and 5,866,699 which are herein incorporated by reference in their entirety.

25

## 5.2 NHPS AND NHP POLYPEPTIDES

NHPs, polypeptides, peptide fragments, mutated, truncated, or deleted forms of the NHPs, and/or NHP fusion proteins can be prepared for a variety of uses. These uses include but are not  
30 limited to the generation of antibodies, as reagents in diagnostic assays, for the identification of other cellular gene products related to a NHP, as reagents in assays for screening for compounds that can be as pharmaceutical reagents useful in the

therapeutic treatment of mental, biological, or medical disorders and diseases. Given the similarity information and expression data, the described NHPs can be targeted (by drugs, oligos, antibodies, etc.) in order to treat disease, or to therapeutically  
5 augment the efficacy of, for example, chemotherapeutic agents used in the treatment of breast or prostate cancer.

The Sequence Listing discloses the amino acid sequences encoded by the described NHP genes. The NHPs typically display have initiator methionines in DNA sequence contexts consistent  
10 with a translation initiation site.

The NHP amino acid sequences of the invention include the amino acid sequence presented in the Sequence Listing as well as analogues and derivatives thereof. Further, corresponding NHP homologues from other species are encompassed by the invention.  
15 In fact, any NHP protein encoded by the NHP nucleotide sequences described above are within the scope of the invention, as are any novel polynucleotide sequences encoding all or any novel portion of an amino acid sequence presented in the Sequence Listing. The degenerate nature of the genetic code is well known, and,  
20 accordingly, each amino acid presented in the Sequence Listing, is generically representative of the well known nucleic acid "triplet" codon, or in many cases codons, that can encode the amino acid. As such, as contemplated herein, the amino acid sequences presented in the Sequence Listing, when taken together  
25 with the genetic code (see, for example, Table 4-1 at page 109 of "Molecular Cell Biology", 1986, J. Darnell et al. eds., Scientific American Books, New York, NY, herein incorporated by reference) are generically representative of all the various permutations and combinations of nucleic acid sequences that can encode such amino  
30 acid sequences.

The invention also encompasses proteins that are functionally equivalent to the NHPs encoded by the presently described nucleotide sequences as judged by any of a number of criteria,



including, but not limited to, the ability to bind and cleave a substrate of a NHP, or the ability to effect an identical or complementary downstream pathway, or a change in cellular metabolism (e.g., proteolytic activity, ion flux, tyrosine phosphorylation, etc.). Such functionally equivalent NHP proteins include, but are not limited to, additions or substitutions of amino acid residues within the amino acid sequence encoded by the NHP nucleotide sequences described above, but which result in a silent change, thus producing a functionally equivalent gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

A variety of host-expression vector systems can be used to express the NHP nucleotide sequences of the invention. Where, as in the present instance, the NHP peptide or polypeptide is thought to be membrane protein, the hydrophobic regions of the protein can be excised and the resulting soluble peptide or polypeptide can be recovered from the culture media. Such expression systems also encompass engineered host cells that express a NHP, or functional equivalent, *in situ*. Purification or enrichment of a NHP from such expression systems can be accomplished using appropriate detergents and lipid micelles and methods well known to those skilled in the art. However, such engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of

the NHP, but to assess biological activity, e.g., in drug screening assays.

The expression systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing NHP nucleotide sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing NHP nucleotide sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing NHP sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing NHP nucleotide sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the NHP product being expressed. For example, when a large quantity of such a protein is to be produced for the generation of pharmaceutical compositions of or containing NHP, or for raising antibodies to a NHP, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which a NHP coding sequence may be ligated individually into the vector in frame with the *lacZ* coding region so that a fusion protein is produced; pIN vectors (Inouye &

Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Pharmacia or American Type Culture Collection) can also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhidrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. A NHP gene coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of NHP gene coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed (e.g., see Smith et al., 1983, J. Virol. 46:584; Smith, U.S. Patent No. 4,215,051).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the NHP nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a NHP product in infected hosts (e.g., See Logan &

Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also be required for efficient translation of inserted NHP nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire NHP gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of a NHP coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (See Bittner et al., 1987, Methods in Enzymol. 153:516-544).

In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to,

CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, human cell lines.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which

5 stably express the NHP sequences described above can be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, 10 polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows 15 cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the NHP product. Such engineered cell lines may be particularly useful in screening and evaluation of 20 compounds that affect the endogenous activity of the NHP product.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc.

25 Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy, et al., 1980, Cell 22:817) genes can be employed in tk<sup>-</sup>, hgp<sup>-</sup> or ap<sup>-</sup> cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to 30 methotrexate (Wigler, et al., 1980, Natl. Acad. Sci. USA 77:3567; O'Hare, et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers

resistance to the aminoglycoside G-418 (Colberre-Garapin, *et al.*, 1981, *J. Mol. Biol.* 150:1); and hygro, which confers resistance to hygromycin (Santerre, *et al.*, 1984, *Gene* 30:147).

Alternatively, any fusion protein can be readily purified by  
5 utilizing an antibody specific for the fusion protein being  
expressed. For example, a system described by Janknecht *et al.*  
allows for the ready purification of non-denatured fusion proteins  
expressed in human cell lines (Janknecht, *et al.*, 1991, *Proc.*  
*Natl. Acad. Sci. USA* 88:8972-8976). In this system, the gene of  
10 interest is subcloned into a vaccinia recombination plasmid such  
that the gene's open reading frame is translationally fused to an  
amino-terminal tag consisting of six histidine residues. Extracts  
from cells infected with recombinant vaccinia virus are loaded  
onto Ni<sup>2+</sup>-nitriloacetic acid-agarose columns and histidine-tagged  
15 proteins are selectively eluted with imidazole-containing buffers.

### 5.3 ANTIBODIES TO NHP PRODUCTS

Antibodies that specifically recognize one or more epitopes  
of a NHP, or epitopes of conserved variants of a NHP, or peptide  
20 fragments of a NHP are also encompassed by the invention. Such  
antibodies include but are not limited to polyclonal antibodies,  
monoclonal antibodies (mAbs), humanized or chimeric antibodies,  
single chain antibodies, Fab fragments, F(ab')<sub>2</sub> fragments,  
fragments produced by a Fab expression library, anti-idiotypic  
25 (anti-Id) antibodies, and epitope-binding fragments of any of the  
above.

The antibodies of the invention may be used, for example, in  
the detection of NHP in a biological sample and may, therefore, be  
utilized as part of a diagnostic or prognostic technique whereby  
30 patients may be tested for abnormal amounts of NHP. Such  
antibodies may also be utilized in conjunction with, for example,  
compound screening schemes for the evaluation of the effect of  
test compounds on expression and/or activity of a NHP gene

product. Additionally, such antibodies can be used in conjunction gene therapy to, for example, evaluate the normal and/or engineered NHP-expressing cells prior to their introduction into the patient. Such antibodies may additionally be used as a method  
5 for the inhibition of abnormal NHP activity. Thus, such antibodies may, therefore, be utilized as part of treatment methods.

For the production of antibodies, various host animals may be immunized by injection with the NHP, an NHP peptide (e.g., one  
10 corresponding the a functional domain of an NHP), truncated NHP polypeptides (NHP in which one or more domains have been deleted), functional equivalents of the NHP or mutated variant of the NHP. Such host animals may include but are not limited to pigs, rabbits, mice, goats, and rats, to name but a few. Various  
15 adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's adjuvant (complete and incomplete), mineral salts such as aluminum hydroxide or aluminum phosphate, surface active substances such as lysolecithin,  
20 pluronic polyols, polyanions, peptides, oil emulsions, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Alternatively, the immune response could be enhanced by combination and or coupling with molecules such as keyhole limpet hemocyanin,  
25 tetanus toxoid, diptheria toxoid, ovalbumin, cholera toxin or fragments thereof. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Monoclonal antibodies, which are homogeneous populations of  
30 antibodies to a particular antigen, can be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975,

Nature 256:495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4:72; Cole et al., 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal

5 Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the  
10 presently preferred method of production.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al., 1985, Nature, 314:452-454) by splicing the genes  
15 from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived  
20 from a murine mAb and a human immunoglobulin constant region. Such technologies are described in U.S. Patents Nos. 6,075,181 and 5,877,397 and their respective disclosures which are herein incorporated by reference in their entirety.

25 Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, 1988, Science 242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al., 1989, Nature 334:544-546) can be adapted to produce single chain antibodies against NHP gene  
30 products. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.



Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include, but are not limited to: the  $F(ab')_2$  fragments which can be produced by pepsin digestion of the antibody molecule and the  
5 Fab fragments which can be generated by reducing the disulfide bridges of the  $F(ab')_2$  fragments. Alternatively, Fab expression libraries may be constructed (Huse *et al.*, 1989, *Science*, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

10 Antibodies to a NHP can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" a given NHP, using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, 1993, *FASEB J* 7(5):437-444; and Nissinoff, 1991, *J. Immunol.* 147(8):2429-2438). For example antibodies which bind  
15 to a NHP domain and competitively inhibit the binding of NHP to its cognate receptor can be used to generate anti-idiotypes that "mimic" the NHP and, therefore, bind and activate or neutralize a receptor. Such anti-idiotypic antibodies or Fab fragments of such anti-idiotypes can be used in therapeutic regimens involving a NHP  
20 mediated pathway.

The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the  
25 scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims. All cited publications, patents,  
30 and patent applications are herein incorporated by reference in their entirety.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising at least 24 contiguous bases of nucleotide sequence first disclosed in the NHP gene described in SEQ ID NO: 23.

2. An isolated nucleic acid molecule comprising a nucleotide sequence that:

- (a) encodes the amino acid sequence shown in SEQ ID NO: 24; and
- (b) hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 23 or the complement thereof.

3. An isolated nucleic acid molecule comprising a nucleotide sequence that:

- (a) encodes the amino acid sequence shown in SEQ ID NO: 2; and
- (b) hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 1 or the complement thereof.

4. An isolated nucleic acid molecule comprising a nucleotide sequence that:

- (a) encodes the amino acid sequence shown in SEQ ID NO: 48; and
- (b) hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 47 or the complement thereof.

# **ABSTRACT**

Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
2220  
2221  
2222  
2223  
2224  
2225  
2226  
2227  
2228  
2229  
2230  
2231  
2232  
223

# PATENT APPLICATION

## DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

ATTORNEY DOCKET NO. LEX-0081-USA

As a below named inventor, I hereby declare that:

My residence/post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Novel Human Transporter Proteins and Polynucleotides Encoding the Same

the specification of which is attached hereto unless the following box is checked:

( ) was filed on \_\_\_\_\_ as US Application Serial No. or PCT International Application  
Number \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR 1.56.

### Foreign Application(s) and/or Claim of Foreign Priority

I hereby claim foreign priority benefits under Title 35, United States Code Section 119 of any foreign application(s) for patent or inventor(s) certificate listed below and have also identified below any foreign application for patent or inventor(s) certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NUMBER	DATE FILED	PRIORITY CLAIMED UNDER 35 U.S.C. 119
			YES: _____ NO: _____
			YES: _____ NO: _____

### Provisional Application

I hereby claim the benefit under Title 35, United States Code Section 119(e) of any United States provisional application(s) listed below:

APPLICATION SERIAL NUMBER	FILING DATE
60/163,018	11/2/1999

### U.S. Priority Claim

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NUMBER	FILING DATE	STATUS(patented/pending/abandoned)

### POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) listed below to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Lance K. Ishimoto, Reg. No. 41866

### Send Correspondence to:

Lance K. Ishimoto  
Lexicon Genetics Incorporated  
4000 Research Forest Drive  
The Woodlands, TX 77381

### Direct Telephone Calls To:

Lance K. Ishimoto  
(281) 362-6554

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION (continued)

ATTORNEY DOCKET NO. LEX-0081-USA

Full Name of Inventor: Marie Harras

Citizenship: Republic of Ireland

Residence: 28717 Driftwood Lane, Spring, TX 77381

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: Gregory Donoho

Citizenship: USA

Residence: 41 Fallenstone Dr., The Woodlands, TX 77381

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: C. Alexander Turner, Jr.

Citizenship: USA

Residence: 67 Winter Wheat Place, The Woodlands, TX 77381

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: Michael C. Nehls

Citizenship: Germany

Residence: Paul-Keller-Strasse 6, Stockdorf, Germany 82131

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: Glenn Friedrich

Citizenship: Canada

Residence: c/o Breland & Breland, Houston, TX 77004

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: Brian Zambrowicz

Citizenship: USA

Residence: 18 Firethorne Place, The Woodlands, TX 77382

Post Office Address: Same

Inventor's Signature

Date

DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION (continued)

ATTORNEY DOCKET NO. LEX-0081-USA

Full Name of Inventor: Arthur T. Sands

Citizenship: USA

Residence: 163 Bristol Bend Circle, The Woodlands, TX 77382

Post Office Address: Same

\_\_\_\_\_  
Inventor's Signature

\_\_\_\_\_  
Date

# SEQUENCE LISTING

<110> Harras, Marie  
Donoho, Gregory  
Turner, C. Alexander Jr.  
Nehls, Michael  
Friedrich, Glenn  
Zambrowicz, Brian  
Sands, Arthur T.

<120> Novel Human Transporter Proteins and  
Polynucleotides Encoding the Same

<130> LEX-0081-USA

<150> US 60/163,018

<151> 1999-11-02

<160> 25

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1977

<212> DNA

<213> homo sapiens

<400> 1

atgacaaaga	tggtctgtga	ggctcagcat	cacacatctg	aggtcagcga	ccagcgcatc	60
cgtgtgacca	gtgaagtctt	cacttgcatt	aagctgatta	aaatgtacac	atgggagaaa	120
ccatttgcga	aaatcattga	agacctaaga	aggaaggaaa	ggaagctatt	ggagagtgct	180
gggcttgtcc	agagccctgac	aagtataacc	ttgttcatca	tccccacagt	ggccacagcg	240
gtctgggttc	tcatccacac	atccttaaag	ctgaatacct	cagcgctcat	ggccttcagc	300
atgctggcct	ccttgaatct	ccttcggctg	tcagtggtct	ttgtgcctat	tcagtgctaaa	360
gggtccagca	attccaaagt	tgcatgtgat	agggtcaaga	agtttttctt	ccaggagagc	420
cctgttttct	atgtccagac	attacaagac	cccagcaaga	ctctgggtct	tgaggaggcc	480
acctgtgcat	ggcaacagac	ctgtcccggt	atcgtcaatg	gggcactgga	gctggagagg	540
aacgggcatg	cttctgaggg	gatgaccagg	cctagagatg	ccctcggggc	agaggaaaga	600
gggaacagcc	tgggccacga	gttgacacag	atcaacctgg	tggtgtccaa	ggggatgatg	660
ttaggggtct	gcggcaacac	ggggagtggt	aagagcagcc	tggtgtcagc	catcctggag	720
gagatgcact	tgctcgaggg	ctcgggtggg	gtgcagggaa	gcctggccta	tgctccccag	780
caggccctga	tgctcagcgg	gaacatcagg	gagaacatcc	tcattgggagg	cgcatatgac	840
aaggcccgat	acctccaggt	gctccactgc	tgctccctga	atcgggacct	ggaactctct	900
ccctttggag	acatgacaga	gattggagag	cggggcctca	acctctctgg	ggggcagaaa	960
cagaggatca	gcctggcccg	cgccgtctat	tcggaccgtc	agatctacct	gctggagcac	1020
cccctgtctg	ctgtggagcg	ccacgtgggg	aagcacattt	ttgaggagtg	cattaaagaag	1080
acactcaggg	gggaagacgt	gcctctgggt	accacacagc	tgcaagtactt	agaattttgt	1140
ggccagatca	ttttgttga	aaatgggaaa	atctgtgaaa	atggaaacta	cagttagtta	1200
atgcagaaaa	aggggaaata	tgcccaactt	atccagaaga	tgcaacaaga	agccactctg	1260
gacatgtttg	aggacacagc	aaagatagca	gagaagccaa	aggtagaaga	tcaggctctg	1320
gccacctccc	tggaagagtc	tctcaacgga	aatgctgtgc	cggagcatca	gctcacacag	1380
gaggaggaga	tggaagaagg	ctccttgagt	tggaggggtc	accaccacta	catccaggca	1440
gctggagggt	acatgtgtct	ttgcataatt	ttcttctctg	tggtgtgtat	cgtctctcta	1500
acgatcttca	gcttctgggt	gatgagctac	tggtttggagc	agggctcggg	gaccaatagc	1560

agccgagaga gcaatggaac catggcagac ctgggcaaca ttgcagacaa tcttcaactg 1620  
 tcttcttacc agctgggtgta cgggctcaac gcctgtctcc tcatctgtgt ggggggtctgc 1680  
 tcttcaggga ttttcaccaa ggtcacgagg aaggcatcca cggccctgca caacaagctc 1740  
 ttcaacaagg ttttccgctg ccccatgagt ttctttgaca ccatcccaat aggcgggctt 1800  
 ttgaactgct tcgcagggga cttggaacag ctggaccagc tcttgcccat cttttcagag 1860  
 cagttctctg tctgttctt aatggtgata gccgtctctg tgattgtcag tgtgtctgtc 1920  
 ccatatatcc tgtaaatggg agccataatc atggttattt gcttcattta ttatatg 1977

<210> 2

<211> 659

<212> PRT

<213> homo sapiens

<400> 2

Met Thr Arg Met Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser  
 1 5 10 15  
 Asp Gln Arg Ile Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu  
 20 25 30  
 Ile Lys Met Tyr Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp  
 35 40 45  
 Leu Arg Arg Lys Glu Arg Lys Leu Leu Glu Lys Cys Gly Leu Val Gln  
 50 55 60  
 Ser Leu Thr Ser Ile Thr Leu Phe Ile Ile Pro Thr Val Ala Thr Ala  
 65 70 75 80  
 Val Trp Val Leu Ile His Thr Ser Leu Lys Leu Lys Leu Thr Ala Ser  
 85 90 95  
 Met Ala Phe Ser Met Leu Ala Ser Leu Asn Leu Leu Arg Leu Ser Val  
 100 105 110  
 Phe Phe Val Pro Ile Ala Val Lys Gly Leu Thr Asn Ser Lys Ser Ala  
 115 120 125  
 Val Met Arg Phe Lys Lys Phe Phe Leu Gln Glu Ser Pro Val Phe Tyr  
 130 135 140  
 Val Gln Thr Leu Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala  
 145 150 155 160  
 Thr Leu Ser Trp Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu  
 165 170 175  
 Glu Leu Glu Arg Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg  
 180 185 190  
 Asp Ala Leu Gly Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu  
 195 200 205  
 His Lys Ile Asn Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys  
 210 215 220  
 Gly Asn Thr Gly Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu  
 225 230 235 240  
 Glu Met His Leu Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala  
 245 250 255  
 Tyr Val Pro Gln Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn  
 260 265 270  
 Ile Leu Met Gly Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu  
 275 280 285  
 His Cys Cys Ser Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp  
 290 295 300  
 Met Thr Glu Ile Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys  
 305 310 315 320  
 Gln Arg Ile Ser Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr  
 325 330 335



Leu Leu Asp Asp Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His  
 340 345 350  
 Ile Phe Glu Glu Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val  
 355 360 365  
 Leu Val Thr His Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile  
 370 375 380  
 Leu Leu Glu Asn Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu  
 385 390 395 400  
 Met Gln Lys Lys Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys  
 405 410 415  
 Glu Ala Thr Ser Asp Met Leu Gln Asp Thr Ala Lys Ile Ala Glu Lys  
 420 425 430  
 Pro Lys Val Glu Ser Gln Ala Leu Ala Thr Ser Leu Glu Glu Ser Leu  
 435 440 445  
 Asn Gly Asn Ala Val Pro Glu His Gln Leu Thr Gln Glu Glu Met  
 450 455 460  
 Glu Glu Gly Ser Leu Ser Trp Arg Val Tyr His His Tyr Ile Gln Ala  
 465 470 475 480  
 Ala Gly Gly Tyr Met Val Ser Cys Ile Ile Phe Phe Phe Val Val Leu  
 485 490 495  
 Ile Val Phe Leu Thr Ile Phe Ser Phe Trp Trp Leu Ser Tyr Trp Leu  
 500 505 510  
 Glu Gln Gly Ser Gly Thr Asn Ser Ser Arg Glu Ser Asn Gly Thr Met  
 515 520 525  
 Ala Asp Leu Gly Asn Ile Ala Asp Asn Pro Gln Leu Ser Phe Tyr Gln  
 530 535 540  
 Leu Val Tyr Gly Leu Asn Ala Leu Leu Leu Ile Cys Val Gly Val Cys  
 545 550 555 560  
 Ser Ser Gly Ile Phe Thr Lys Val Thr Arg Lys Ala Ser Thr Ala Leu  
 565 570 575  
 His Asn Lys Leu Phe Asn Lys Val Phe Arg Cys Pro Met Ser Phe Phe  
 580 585 590  
 Asp Thr Ile Pro Ile Gly Arg Leu Leu Asn Cys Phe Ala Gly Asp Leu  
 595 600 605  
 Glu Gln Leu Asp Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val  
 610 615 620  
 Leu Ser Leu Met Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser  
 625 630 635 640  
 Pro Tyr Ile Leu Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile  
 645 650 655  
 Tyr Tyr Met

<210> 3  
 <211> 2115  
 <212> DNA  
 <213> homo sapiens

<400> 3  
 atgacaagaa tggctgtgaa ggctcagcat cacacatctg aggtcagcga ccagcgcatc 60  
 cgtgtgacca gtgaagttct cacttgcatt aagctgatta aaatgtacac atgggagaaa 120  
 ccatttgcga aaatcattga agacctaaga aggaaggaaa ggaagctatt ggagaagtgc 180  
 gggcttgtcc agagcctgac aagtataacc ttgttcacat tcccacagt gccacagcg 240  
 gtctgggttc tcattccacac atccttaaag ctgaaactca cagcgctcaat ggccttcagc 300  
 atgtctggcct ccttgaatct ccttcggctg tcagtggtct ttgtgcctat tgcagtcaaa 360  
 ggtctcacga attccaaatc tgcagtgatg aggttcaaga agtttttctt ccaggagagc 420

cctgttttct	atgtccagac	attacaagac	cccagcaag	ctctggttct	tgaggaggcc	480
accttgtcat	ggcaacagac	ctgtcccggt	atcgtaaatg	gggcaactga	gctggagagg	540
aacgggcatg	ctctcgaggg	gatgaccagg	cctagagatg	cctctggggc	agagggaaga	600
gggaacagcc	tgggcccaga	gttgcaaca	atcaacctgg	tgggtgccaa	ggggatgatg	660
ttaggggtct	cgggcaacac	ggggagtggg	aagagcagcc	tgttgtagc	catctctggg	720
gagatgcact	tgtctgaggg	ctcgggtggg	gtgcaggaaa	gctctggccta	tgtccccccg	780
caggcctgga	tcgtacaggg	gaacatcagg	gagaacatcc	tcattggagg	cgcatatgac	840
aaggcccgat	acctccaggt	gctccactgc	tgtccctcga	atcgggacct	ggaactctct	900
ccctttggag	acatgacaga	gattggagag	cggggcctca	acctctctct	ggggcagaaa	960
cagagatcca	gcctggcccg	cgccgtctat	tccgaccgtc	agatctacct	gctccagcac	1020
ccctctgtct	ctgtggagcg	ccacgtgggg	aagcacattt	ttgaggagtg	cattaaagaag	1080
acactcaggg	ggaagcaggg	cgctctgggt	accaccagc	tcagctactt	agcaatttgg	1140
ggccagatca	ttttgttgga	aaatgggaaa	atctgtgaaa	atggaactca	cagtgtagtt	1200
atgcagaaaa	aggggaaaaa	tgccccactt	atccagaaga	tgcaacaagg	agccactctg	1260
gacatgttgc	aggacacagc	aaagatagca	gagaagccaa	aggtagaaa	tcaggctctg	1320
gcacactccc	tgggaagatc	tctcaacgga	aatgctgtgc	cggagcatca	gctcacacag	1380
gaggagagga	tgggaagaag	ctccttgagt	tggagggtct	accaccacta	catccaggca	1440
gctggagggt	acatggtctc	ttgcataa	ttcttctctg	tgggtctgat	cgtctcttta	1500
acgatctcca	gcttctgggt	gctgagctac	tgggtggagc	agggtctggg	gaccaatagc	1560
agccgagaga	gcaatgggaa	catggcagac	ctgggcaaca	ctgcagacaa	tcctcaactg	1620
tccttctacc	agctggtgta	cgggctcaac	gcctgtcttc	tcattctgtg	gggggtctgc	1680
tcctcaggga	ttttcaccaa	ggtcacgagg	aaggcatcca	cggccctgca	caacagctc	1740
ttcaacaagg	ttttccgtct	ccccatgagt	ttctttgaca	ccatcccaat	agcccggtct	1800
ttgaactgct	tcgcaggagg	cttggaacag	ctggaccagg	ctttgcccac	cttttcagag	1860
cagtctctgt	tcctgtcctt	aatgggtgac	gccgtctctg	tgattgtcag	tgtgtcgtct	1920
ccatatatcc	tgtaaatggg	agccataatc	atggttat	tgcttcat	ttatatgatg	1980
ttcaagaagg	ccatcggtgt	gttcaagaga	ctggagaact	atagccggta	tcctttatcc	2040
tcaccatcca	tcaattctct	gcaaggcctg	agctccatcc	atgtctatgg	aaaaactgaa	2100
gacttcatca	gocag					2115

<210> 4

<211> 705

<212> PRT

<213> homo sapiens

<400> 4

Met	Thr	Arg	Met	Ala	Val	Lys	Ala	Gln	His	His	Thr	Ser	Glu	Val	Ser
1			5					10					15		
Asp	Gln	Arg	Ile	Arg	Val	Thr	Ser	Glu	Val	Leu	Thr	Cys	Ile	Lys	Leu
		20						25				30			
Ile	Lys	Met	Tyr	Thr	Trp	Glu	Lys	Pro	Phe	Ala	Lys	Ile	Ile	Glu	Asp
		35					40					45			
Leu	Arg	Arg	Lys	Glu	Arg	Lys	Leu	Leu	Glu	Lys	Cys	Gly	Leu	Val	Gln
		50				55					60				
Ser	Leu	Thr	Ser	Ile	Thr	Leu	Phe	Ile	Ile	Pro	Thr	Val	Ala	Thr	Ala
		65			70				75					80	
Val	Trp	Val	Leu	Ile	His	Thr	Ser	Leu	Lys	Leu	Lys	Leu	Thr	Ala	Ser
				85					90					95	
Met	Ala	Phe	Ser	Met	Leu	Ala	Ser	Leu	Asn	Leu	Leu	Arg	Leu	Ser	Val
			100				105						110		
Phe	Phe	Val	Pro	Ile	Ala	Val	Lys	Gly	Leu	Thr	Asn	Ser	Lys	Ser	Ala
		115					120					125			
Val	Met	Arg	Phe	Lys	Lys	Phe	Phe	Leu	Gln	Glu	Ser	Pro	Val	Phe	Tyr
		130				135					140				
Val	Gln	Thr	Leu	Gln	Asp	Pro	Ser	Lys	Ala	Leu	Val	Phe	Glu	Glu	Ala
		145			150					155				160	

Thr	Leu	Ser	Trp	Gln	Gln	Thr	Cys	Pro	Gly	Ile	Val	Asn	Gly	Ala	Leu	165	170	175
Glu	Leu	Glu	Arg	Asn	Gly	His	Ala	Ser	Glu	Gly	Met	Thr	Arg	Pro	Arg	180	185	190
Asp	Ala	Leu	Gly	Pro	Glu	Glu	Glu	Gly	Asn	Ser	Leu	Gly	Pro	Glu	Leu	195	200	205
His	Lys	Ile	Asn	Leu	Val	Val	Ser	Lys	Gly	Met	Met	Leu	Gly	Val	Cys	210	215	220
Gly	Asn	Thr	Gly	Ser	Gly	Lys	Ser	Ser	Leu	Leu	Ser	Ala	Ile	Leu	Glu	225	230	235
Glu	Met	His	Leu	Leu	Glu	Gly	Ser	Val	Gly	Val	Gln	Gly	Ser	Leu	Ala	245	250	255
Tyr	Val	Pro	Gln	Gln	Ala	Trp	Ile	Val	Ser	Gly	Asn	Ile	Arg	Glu	Asn	260	265	270
Ile	Leu	Met	Gly	Gly	Ala	Tyr	Asp	Lys	Ala	Arg	Tyr	Leu	Gln	Val	Leu	275	280	285
His	Cys	Cys	Ser	Leu	Asn	Arg	Asp	Leu	Glu	Leu	Leu	Pro	Phe	Gly	Asp	290	295	300
Met	Thr	Glu	Ile	Gly	Glu	Arg	Gly	Leu	Asn	Leu	Ser	Gly	Gly	Gln	Lys	305	310	315
Gln	Arg	Ile	Ser	Leu	Ala	Arg	Ala	Val	Tyr	Ser	Asp	Arg	Gln	Ile	Tyr	325	330	335
Leu	Leu	Asp	Asp	Pro	Leu	Ser	Ala	Val	Asp	Ala	His	Val	Gly	Lys	His	340	345	350
Ile	Phe	Glu	Glu	Cys	Ile	Lys	Lys	Thr	Leu	Arg	Gly	Lys	Thr	Val	Val	355	360	365
Leu	Val	Thr	His	Gln	Leu	Gln	Tyr	Leu	Glu	Phe	Cys	Gly	Gln	Ile	Ile	370	375	380
Leu	Leu	Glu	Asn	Gly	Lys	Ile	Cys	Glu	Asn	Gly	Thr	His	Ser	Glu	Leu	385	390	395
Met	Gln	Lys	Lys	Gly	Lys	Tyr	Ala	Gln	Leu	Ile	Gln	Lys	Met	His	Lys	405	410	415
Glu	Ala	Thr	Ser	Asp	Met	Leu	Gln	Asp	Thr	Ala	Lys	Ile	Ala	Glu	Lys	420	425	430
Pro	Lys	Val	Glu	Ser	Gln	Ala	Leu	Ala	Thr	Ser	Leu	Glu	Glu	Ser	Leu	435	440	445
Asn	Gly	Asn	Ala	Val	Pro	Glu	His	Gln	Leu	Thr	Gln	Glu	Glu	Glu	Met	450	455	460
Glu	Glu	Gly	Ser	Leu	Ser	Trp	Arg	Val	Tyr	His	His	Tyr	Ile	Gln	Ala	465	470	475
Ala	Gly	Gly	Tyr	Met	Val	Ser	Cys	Ile	Ile	Phe	Phe	Phe	Val	Val	Leu	485	490	495
Ile	Val	Phe	Leu	Thr	Ile	Phe	Ser	Phe	Trp	Trp	Leu	Ser	Tyr	Trp	Leu	500	505	510
Glu	Gln	Gly	Ser	Gly	Thr	Asn	Ser	Ser	Arg	Glu	Ser	Asn	Gly	Thr	Met	515	520	525
Ala	Asp	Leu	Gly	Asn	Ile	Ala	Asp	Asn	Pro	Gln	Leu	Ser	Phe	Tyr	Gln	530	535	540
Leu	Val	Tyr	Gly	Leu	Asn	Ala	Leu	Leu	Leu	Ile	Cys	Val	Gly	Val	Cys	545	550	555
Ser	Ser	Gly	Ile	Phe	Thr	Lys	Val	Thr	Arg	Lys	Ala	Ser	Thr	Ala	Leu	565	570	575
His	Asn	Lys	Leu	Phe	Asn	Lys	Val	Phe	Arg	Cys	Pro	Met	Ser	Phe	Phe	580	585	590
Asp	Thr	Ile	Pro	Ile	Gly	Arg	Leu	Leu	Asn	Cys	Phe	Ala	Gly	Asp	Leu	595	600	605

Glu Gln Leu Asp Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val  
 610 615 620  
 Leu Ser Leu Met Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser  
 625 630 635 640  
 Pro Tyr Ile Leu Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile  
 645 650 655  
 Tyr Tyr Met Met Phe Lys Lys Ala Ile Gly Val Phe Lys Arg Leu Glu  
 660 665 670  
 Asn Tyr Ser Arg Ser Pro Leu Phe Ser His Ile Leu Asn Ser Leu Gln  
 675 680 685  
 Gly Leu Ser Ser Ile His Val Tyr Gly Lys Thr Glu Asp Phe Ile Ser  
 690 695 700  
 Gln  
 705

<210> 5  
 <211> 3189  
 <212> DNA  
 <213> homo sapiens

<400> 5  
 atgacaagaa tggctgtgaa ggctcagcat cacacatctg aggtcagcga ccagcgcctc 60  
 cgtgtgacca gtgaagtctt cacttgcatt aagctgatta aaatgtacac atgggagaaa 120  
 ccatttgcaa aaatcattga agacattaaga aggaagggaaa ggaagctatt ggagaagtgc 180  
 gggccttgctc agagcctgac aagtataacc ttgttcacat tcccacacagt ggccacagcg 240  
 gtctgggttc tcatccacac atccttaaag ctgaaactca cagcgtaaat ggccctcagc 300  
 atgctgggctt ccttgaatct ccttcggctg tcagtgttct tgcagtcaaa tgcagtcaaa 360  
 ggcttcacga attccaagtc tgcagtgatg aggttcaaga agtttttctt ccagggagagc 420  
 cctgttttct atgtccagac attacaagac ccagcgaag ccttggtctt tgaggaggcc 480  
 accttgtcat ggcaacagac ctgtcccggg atcgtcaatg gggcacttga gctggagagg 540  
 aacgggcatg cttctgaggg gatgaccagg cctagagatg cctcggggcc agagaaagaa 600  
 gggaacagcc tgggcccaga gttgcacaag atcaacctgg tgggtgtccaa ggggatgatg 660  
 ttagggttct gcggcaacac ggggagtgtt aagagcagcc tgtgtgcagc catcctggag 720  
 gagatgcact tgcctgaggc ctcggtgggg gtgcagggaa gcttgcccta tgtcccccag 780  
 caggccttga tgcctcagcg gaacatcagg gagaacatcc tcatggggagg cgcataatgac 840  
 aaggcccgat acctccaggt gctccactgc tgctccctga atcgggacct ggaacttctg 900  
 ccttttggag acatgacaga gattggagag cggggcctca acctcttgg ggggcagaaa 960  
 cagaggaatca gcttggcccg cgccgtctat tccgaccgtc agatctacct gctggacgac 1020  
 cccctgtctc ctgtggagcc ccacgtgggg aagcacattt ttgaggagtg cattaagaag 1080  
 acactcaggg ggaagacggt cgtcctgttg acccaccagc tgcagtactt agaattttgt 1140  
 ggccagatca ttttgttggg aaatgggaaa atctgtgaaa atggaactca cagttagtta 1200  
 atgcagaaaa aggggaaata tgcccgaact atccagaaga tgcacaagga agccactctg 1260  
 gacatgttgc aggcacagcg aaagatagca gagaagccaa aggtagaaga tcaggctctg 1320  
 gccactcccc tggaaagatc tctcaacgga aatgctgtgc cggagcatca gctcaacagc 1380  
 gaggaggaga tggaaagagg ctcttgagt tggagggtct accaccacta catccagcca 1440  
 gctggagggt acatggtctc ttgcataatt ttcttcttcg tgggtctgat cgtcttctta 1500  
 acgatcttca gcttctgggt gctgagctac tgggttgagc agggctcggg gaccaatagc 1560  
 agccgagaga gcaatggaac catggcagac ctgggcaaca tctgacacaa tgcctcaactg 1620  
 tccctctacc agcttggtgt agcgttctcc gccctgtctc tcatctgtgt ggggtgtctg 1680  
 tccctcagga ttttcaccaa ggctcagcagg aaggcatcca cgcccttga caacaagctc 1740  
 ttcaacagga ttttcgcgtc ccccatgagt ttctttgaca ccatcccaat aggcctcgtt 1800  
 tgaactgtct tgcagcggga ctgggaaacag ctggaccagc tcttgcccat cttttcagag 1860  
 cagttctctg tctctgtcct aatggtgata gcgcctctgt tgattgtcag ttgtctgtct 1920  
 ccatatattc tgtaaatggg agccataatc atggttattt gcttcattta ttaatatgat 1980  
 ttcaagaagg ccatcgggtg gttcaagaga ctggagaact atagccggtc tcccttatct 2040  
 tcccacatcc tcaattctct gcaaggcctg agctccatcc atgtctatgg aaaaactgaa 2100

gacttcatca	gccagtttaa	gaggctgact	gatgcgcaga	ataactacct	gctgttggtt	2160
ctatcttcca	cacgatggat	ggcattgagg	ctggagatca	tgaccaacct	tgtgacctgt	2220
gctgttgccc	tgttcgtggc	ttttggcatt	tcctccaccc	ctactccctt	taaagtcatg	2280
gctgtcaaca	tcgtgctgca	gctggcgctc	agcttccagg	ccactgcccg	gattggcgtg	2340
gagacagagg	cacagttcac	ggctgtagag	aggatactgc	agtacatgaa	gatgtgtgtc	2400
tcggaagctc	ctttacacat	ggaaggcaca	agttgtcccc	aggggtggcc	acacgcatgg	2460
gaaatcatat	ttcaggatta	tcacatgaaa	tacagagaca	acacaccacc	cgtgcttcac	2520
ggcatcaacc	tgaccatccg	cggccacgaa	gtggtggcca	tcgtgggaag	gaacggctct	2580
gggaagtcc	ccttgggcat	ggctctcttc	cgctgtgtgg	agcccatggc	agggcggtat	2640
ctcattgacg	gcgtggacat	ttgcagcatc	ggcctggagg	acttgcgttc	caagctctca	2700
gtgatccctc	aagatccagt	gctgctctca	ggaaccatca	gattcaacct	agatcccttt	2760
gaccgtcaca	ctgaccagca	gatctgggat	gccttggaga	ggacattcct	gaccaaggcc	2820
atctcaaaat	tcctcaaaaa	gctgcataca	gatgtgtgtg	aaaacggtgg	aaacttctct	2880
gtgggggaga	ggcagctgct	ctgcattgcc	aggcgtgtgc	ttcgcaactc	caagatcatc	2940
cttatcgatg	aagccacagg	ctccattgac	atggagacag	acacccatgat	cacgcgcaca	3000
atccgtgaag	ccttccaggg	ctgcaccgtg	ctcgtcattg	cccaccgtgt	caccactgtg	3060
ctgaactgtg	accacatcct	ggttatgggc	aatgggaagg	tggtagaatt	tgatcggccg	3120
gaggtactgc	ggaagaagcc	tggtgtcattg	ttgcagcccc	tcattggccac	agccacttct	3180
tcactgaga						3189

<210> 6

<211> 1063

<212> PRT

<213> homo sapiens

<400> 6

Met	Thr	Arg	Met	Ala	Val	Lys	Ala	Gln	His	His	Thr	Ser	Glu	Val	Ser
1				5				10						15	
Asp	Gln	Arg	Ile	Arg	Val	Thr	Ser	Glu	Val	Leu	Thr	Cys	Ile	Lys	Leu
			20					25					30		
Ile	Lys	Met	Tyr	Thr	Trp	Glu	Lys	Pro	Phe	Ala	Lys	Ile	Ile	Glu	Asp
			35				40					45			
Leu	Arg	Arg	Lys	Glu	Arg	Lys	Leu	Leu	Glu	Lys	Cys	Gly	Leu	Val	Gln
	50					55					60				
Ser	Leu	Thr	Ser	Ile	Thr	Leu	Phe	Ile	Ile	Pro	Thr	Val	Ala	Thr	Ala
65					70					75				80	
Val	Trp	Val	Leu	Ile	His	Thr	Ser	Leu	Lys	Leu	Lys	Leu	Thr	Ala	Ser
			85						90					95	
Met	Ala	Phe	Ser	Met	Leu	Ala	Ser	Leu	Asn	Leu	Leu	Arg	Leu	Ser	Val
			100					105					110		
Phe	Phe	Val	Pro	Ile	Ala	Val	Lys	Gly	Leu	Thr	Asn	Ser	Lys	Ser	Ala
115							120					125			
Val	Met	Arg	Phe	Lys	Lys	Phe	Phe	Leu	Gln	Glu	Ser	Pro	Val	Phe	Tyr
130						135					140				
Val	Gln	Thr	Leu	Gln	Asp	Pro	Ser	Lys	Ala	Leu	Val	Phe	Glu	Glu	Ala
145					150					155					160
Thr	Leu	Ser	Trp	Gln	Gln	Thr	Cys	Pro	Gly	Ile	Val	Asn	Gly	Ala	Leu
			165						170					175	
Glu	Leu	Glu	Arg	Asn	Gly	His	Ala	Ser	Glu	Gly	Met	Thr	Arg	Pro	Arg
			180					185					190		
Asp	Ala	Leu	Gly	Pro	Glu	Glu	Glu	Gly	Asn	Ser	Leu	Gly	Pro	Glu	Leu
			195				200					205			
His	Lys	Ile	Asn	Leu	Val	Val	Ser	Lys	Gly	Met	Met	Leu	Gly	Val	Cys
210						215					220				
Gly	Asn	Thr	Gly	Ser	Gly	Lys	Ser	Ser	Leu	Leu	Ser	Ala	Ile	Leu	Glu
225					230					235					

Glu Met His Leu Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala  
 245 250 255  
 Tyr Val Pro Gln Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn  
 260 265 270  
 Ile Leu Met Gly Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu  
 275 280 285  
 His Cys Ser Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp  
 290 295 300  
 Met Thr Glu Ile Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys  
 305 310 315 320  
 Gln Arg Ile Ser Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr  
 325 330 335  
 Leu Leu Asp Asp Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His  
 340 345 350  
 Ile Phe Glu Glu Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val  
 355 360 365  
 Leu Val Thr His Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile  
 370 375 380  
 Leu Leu Glu Asn Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu  
 385 390 395 400  
 Met Gln Lys Lys Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys  
 405 410 415  
 Glu Ala Thr Ser Asp Met Leu Gln Asp Thr Ala Lys Ile Ala Glu Lys  
 420 425 430  
 Pro Lys Val Glu Ser Gln Ala Leu Ala Thr Ser Leu Glu Glu Ser Leu  
 435 440 445  
 Asn Gly Asn Ala Val Pro Glu His Gln Leu Thr Gln Glu Glu Met  
 450 455 460  
 Glu Glu Gly Ser Leu Ser Trp Arg Val Tyr His His Tyr Ile Gln Ala  
 465 470 475 480  
 Ala Gly Gly Tyr Met Val Ser Cys Ile Ile Phe Phe Phe Val Val Leu  
 485 490 495  
 Ile Val Phe Leu Thr Ile Phe Ser Phe Trp Trp Leu Ser Tyr Trp Leu  
 500 505 510  
 Glu Gln Gly Ser Gly Thr Asn Ser Ser Arg Glu Ser Asn Gly Thr Met  
 515 520 525  
 Ala Asp Leu Gly Asn Ile Ala Asp Asn Pro Gln Leu Ser Phe Tyr Gln  
 530 535 540  
 Leu Val Tyr Gly Leu Asn Ala Leu Leu Leu Ile Cys Val Gly Val Cys  
 545 550 555 560  
 Ser Ser Gly Ile Phe Thr Lys Val Thr Arg Lys Ala Ser Thr Ala Leu  
 565 570 575  
 His Asn Lys Leu Phe Asn Lys Val Phe Arg Cys Pro Met Ser Phe Phe  
 580 585 590  
 Asp Thr Ile Pro Ile Gly Arg Leu Leu Asn Cys Phe Ala Gly Asp Leu  
 595 600 605  
 Glu Gln Leu Asp Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val  
 610 615 620  
 Leu Ser Leu Met Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser  
 625 630 635 640  
 Pro Tyr Ile Leu Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile  
 645 650 655  
 Tyr Tyr Met Met Phe Lys Lys Ala Ile Gly Val Phe Lys Arg Leu Glu  
 660 665 670  
 Asn Tyr Ser Arg Ser Pro Leu Phe Ser His Ile Leu Asn Ser Leu Gln  
 675 680 685

Gly Leu Ser Ser Ile His Val Tyr Gly Lys Thr Glu Asp Phe Ile Ser  
 690 695 700  
 Gln Phe Lys Arg Leu Thr Asp Ala Gln Asn Asn Tyr Leu Leu Leu Phe  
 705 710 715 720  
 Leu Ser Ser Thr Arg Trp Met Ala Leu Arg Leu Glu Ile Met Thr Asn  
 725 730 735  
 Leu Val Thr Leu Ala Val Ala Leu Phe Val Ala Phe Gly Ile Ser Ser  
 740 745 750  
 Thr Pro Tyr Ser Phe Lys Val Met Ala Val Asn Ile Val Leu Gln Leu  
 755 760 765  
 Ala Ser Ser Phe Gln Ala Thr Ala Arg Ile Gly Leu Glu Thr Glu Ala  
 770 775 780  
 Gln Phe Thr Ala Val Glu Arg Ile Leu Gln Tyr Met Lys Met Cys Val  
 785 790 795 800  
 Ser Glu Ala Pro Leu His Met Glu Gly Thr Ser Cys Pro Gln Gly Trp  
 805 810 815  
 Pro Gln His Gly Glu Ile Ile Phe Gln Asp Tyr His Met Lys Tyr Arg  
 820 825 830  
 Asp Asn Thr Pro Thr Val Leu His Gly Ile Asn Leu Thr Ile Arg Gly  
 835 840 845  
 His Glu Val Val Gly Ile Val Gly Arg Thr Gly Ser Gly Lys Ser Ser  
 850 855 860  
 Leu Gly Met Ala Leu Phe Arg Leu Val Glu Pro Met Ala Gly Arg Ile  
 865 870 875 880  
 Leu Ile Asp Gly Val Asp Ile Cys Ser Ile Gly Leu Glu Asp Leu Arg  
 885 890 895  
 Ser Lys Leu Ser Val Ile Pro Gln Asp Pro Val Leu Leu Ser Gly Thr  
 900 905 910  
 Ile Arg Phe Asn Leu Asp Pro Phe Asp Arg His Thr Asp Gln Gln Ile  
 915 920 925  
 Trp Asp Ala Leu Glu Arg Thr Phe Leu Thr Lys Ala Ile Ser Lys Phe  
 930 935 940  
 Pro Lys Lys Leu His Thr Asp Val Val Glu Asn Gly Gly Asn Phe Ser  
 945 950 955 960  
 Val Gly Glu Arg Gln Leu Leu Cys Ile Ala Arg Ala Val Leu Arg Asn  
 965 970 975  
 Ser Lys Ile Ile Leu Ile Asp Glu Ala Thr Ala Ser Ile Asp Met Glu  
 980 985 990  
 Thr Asp Thr Leu Ile Gln Arg Thr Ile Arg Glu Ala Phe Gln Gly Cys  
 995 1000 1005  
 Thr Val Leu Val Ile Ala His Arg Val Thr Thr Val Leu Asn Cys Asp  
 1010 1015 1020  
 His Ile Leu Val Met Gly Asn Gly Lys Val Val Glu Phe Asp Arg Pro  
 1025 1030 1035 1040  
 Glu Val Leu Arg Lys Lys Pro Gly Ser Leu Phe Ala Ala Leu Met Ala  
 1045 1050 1055  
 Thr Ala Thr Ser Ser Leu Arg  
 1060

<210> 7

<211> 1488

<212> DNA

<213> homo sapiens

<400> 7

atgacaagaa tggctgtgaa ggctcagcat cacacatctg aggtcagcga ccagcgcac

60

cggtgtgacca	gtgaagtctt	cacttgcatt	aagctgatta	aaatgtacac	atggggagaaa	120
ccatttgcac	aaatcattga	agacctaaga	aggaaggaaa	ggaagctatt	ggagaagtgc	180
gggcttgttc	agagcctgac	aagtataacc	ttgttcacac	tccccacagt	ggccacagcg	240
gtctgggttc	tcatccacac	atccttaaa	ctgaaactca	cagcgctcaat	ggccttcagc	300
atgctggcct	ccttgaatct	ccttcggctg	tcagtggtct	ttgtgcctat	tcgagtcaca	360
ggctctcaga	attccaaagt	tcagtgatg	agggttcaaga	agtttttctt	ccaggagagc	420
cctgttttct	atgtccagac	attacaagac	cccagcaaa	ctctgggtctt	tgaggaggcc	480
accttgtcat	ggcaacagac	ctgtcccggg	atcgtcaatg	gggcactgga	gctggagagg	540
aacggggcatg	cttctgaggg	gatgaccagg	cctagagatg	ccctcgggcc	agaggaagaa	600
gggaacagcc	tggggcccaga	gttgcaaca	atcaacctgg	tgtgttccaa	ggggatgatg	660
ttaggggtct	ggggcaacac	ggggagtgtt	aagagcagcc	tggtgtcagc	catcctggag	720
gagatgcact	tgctcagggg	ctcgtggggg	gtgcaggaaa	gcctggccta	tgccccccag	780
caggcctgga	tcgtcagcgg	gaacatcagg	gagaaacatc	tcattgggag	gcgcatatgac	840
aaggcccgat	acctccaggt	gctccactgc	tgctccctga	atcggggacct	ggaactctctg	900
ccctttggag	acatgacaga	gattggagag	cggggcctca	acctctctgg	ggggcagaaa	960
cagaggatca	gcttgggccg	cgccgtctat	tcgcagcctg	agatctacct	gctggcagcag	1020
ccctgtctct	ctgtggacgc	ccacgtgggg	aagcacattt	ttgaggagtg	cattagaagag	1080
acactcaggg	ggaagacggt	cgctctgggt	accaccagc	tcgactactt	agaattttgt	1140
ggccagatca	ttttgttggg	aaatgggaaa	atctgtgaaa	atggaactca	cagtgagtta	1200
atgcagaaaa	aggggaaata	tgcccaactt	atccagaaga	tgccacaagg	agccactctg	1260
gttttccgct	gcgccatgag	tttctttgac	accatcccaa	tagggccggt	tttgaactgc	1320
ttcgcagggg	acttgggaca	ctctggaccag	ctcttgccca	tcctttcaga	gcagtttctg	1380
gtcctgtctc	taatggtgat	cgccgtcctg	ttgattgtca	gtgtgctgtc	tccatatatc	1440
ctgttaatgg	gagccataat	catgggttatt	tgcttcattt	attatatg		1488

<210> 8

<211> 496

<212> PRT

<213> homo sapiens

<400> 8

Met	Thr	Arg	Met	Ala	Val	Lys	Ala	Gln	His	His	Thr	Ser	Glu	Val	Ser
1				5				10						15	
Asp	Gln	Arg	Ile	Arg	Val	Thr	Ser	Glu	Val	Leu	Thr	Cys	Ile	Lys	Leu
			20					25					30		
Ile	Lys	Met	Tyr	Thr	Trp	Glu	Lys	Pro	Phe	Ala	Lys	Ile	Ile	Glu	Asp
			35				40					45			
Leu	Arg	Arg	Lys	Glu	Arg	Lys	Leu	Leu	Glu	Lys	Cys	Gly	Leu	Val	Gln
	50				55					60					
Ser	Leu	Thr	Ser	Ile	Thr	Leu	Phe	Ile	Ile	Pro	Thr	Val	Ala	Thr	Ala
65				70					75					80	
Val	Trp	Val	Leu	Ile	His	Thr	Ser	Leu	Lys	Leu	Lys	Leu	Thr	Ala	Ser
			85					90					95		
Met	Ala	Phe	Ser	Met	Leu	Ala	Ser	Leu	Asn	Leu	Leu	Arg	Leu	Ser	Val
	100						105						110		
Phe	Phe	Val	Pro	Ile	Ala	Val	Lys	Gly	Leu	Thr	Asn	Ser	Lys	Ser	Ala
	115						120						125		
Val	Met	Arg	Phe	Lys	Lys	Phe	Phe	Leu	Gln	Glu	Ser	Pro	Val	Phe	Tyr
	130					135				140					
Val	Gln	Thr	Leu	Gln	Asp	Pro	Ser	Lys	Ala	Leu	Val	Phe	Glu	Glu	Ala
145				150					155					160	
Thr	Leu	Ser	Trp	Gln	Gln	Thr	Cys	Pro	Gly	Ile	Val	Asn	Gly	Ala	Leu
			165					170					175		
Glu	Leu	Glu	Arg	Asn	Gly	His	Ala	Ser	Glu	Gly	Met	Thr	Arg	Pro	Arg
	180						185					190			
Asp	Ala	Leu	Gly	Pro	Glu	Glu	Glu	Gly	Asn	Ser	Leu	Gly	Pro	Glu	Leu



195	200	205
His Lys Ile Asn Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys		
210	215	220
Gly Asn Thr Gly Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu		
225	230	235
Glu Met His Leu Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala		
245	250	255
Tyr Val Pro Gln Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn		
260	265	270
Ile Leu Met Gly Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu		
275	280	285
His Cys Cys Ser Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp		
290	295	300
Met Thr Glu Ile Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys		
305	310	315
Gln Arg Ile Ser Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr		
325	330	335
Leu Leu Asp Asp Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His		
340	345	350
Ile Phe Glu Glu Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val		
355	360	365
Leu Val Thr His Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile		
370	375	380
Leu Leu Glu Asn Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu		
385	390	395
Met Gln Lys Lys Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys		
405	410	415
Glu Ala Thr Ser Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile		
420	425	430
Pro Ile Gly Arg Leu Leu Asn Cys Phe Ala Gly Asp Leu Glu Gln Leu		
435	440	445
Asp Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val Leu Ser Leu		
450	455	460
Met Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile		
465	470	475
Leu Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met		
485	490	495

<210> 9

<211> 1626

<212> DNA

<213> homo sapiens

<400> 9

atgacaagaa	tggctgtgaa	ggctcagcat	cacacatctg	aggctcagcga	ccagcgcctc	60
cgtgtgacca	gtgaagttct	cactttgcat	aagctgatta	aaatgtacac	atgggagaaa	120
ccatttgcga	aaatcattga	agacctaaga	aggaaggaaa	ggaagctatt	ggagaagtgc	180
gggtgtgttc	agagcctgac	aagtataacc	tgttccatca	tccccacagt	ggccacagcg	240
gtctgggttc	tcattccacac	atccttaaaag	ctgaaactca	cagcgtcaat	ggccttcagc	300
atgtcggcct	ccttgaatct	ccttcggctg	tcagtggtct	ttgtgcctat	tcagtcctaaa	360
gggtccacga	attccaagtc	tgcatgtgat	aggttcaaga	agtttttctc	ccaggagagc	420
cctgttttct	atgtccagac	attacaagac	cccagcaaaag	ctctgtgtct	tgaggaggcc	480
accttctcat	ggcaacagac	ctgtcccggg	atcgtcaatg	gggcactgga	gctggagagg	540
aacggggcatg	cttctgaggg	gatgaccagg	cctagagatg	cctcggggcc	agaggaagaa	600
gggaacagcc	tgggcccaga	gttgacaaag	atcaacctgg	tggtgtccaa	ggggatgatg	660
ttaggggctc	gcggcaacac	ggggagtggt	aagagcagcc	tggtgtcagc	catcctggag	720

gagatgcact	tgctcgagg	ctcgtgggg	gtgcaggaa	gcctggccta	tgccccag	780
caggccctga	tcgtcagcg	gaacatcag	gagaacatcc	tcattgggagg	cgcatatgac	840
aaggcccgat	acctccagg	gctccactgc	tgctccctga	atcgggacct	ggaactctctg	900
ccctttggag	acatgacaga	gattggagag	cggggacctca	acctctctgg	ggggcagaaa	960
cagaggatca	gcctggccc	cgccgtctat	tcgacccgtc	agatctacct	gctggacgac	1020
ccctgtgtctg	ctgtggacgc	ccacgtgggg	aagcacattt	ttgaggagtg	cattaagaag	1080
acactcagg	ggaagacggt	cgctctgggt	accaccacgc	tcgagtactt	agaattttgt	1140
ggccagatca	ttttgttgg	aaatgggaaa	atctgtgaaa	atggaaactca	cagtgaagtta	1200
atgcagaaaa	aggggaaata	tgcccaactt	atccagaaga	tgacaaagga	agccacttgc	1260
gttttccgct	gcccctgag	tttctttgac	accatcccaa	tagggccgct	tttgaactgc	1320
ttcgaggagg	acttggaaaca	gctggaccag	ctcttgccca	ctttttcaga	gcagttcctg	1380
gtcctgtcct	taatgggtgat	cgccgtcctg	ttgattgtca	gtgtgctgtc	tcctatatc	1440
ctgttaatgg	gagccataat	catgggtatt	tgcttcattt	attatatgat	gttcaagaag	1500
gccatcggtg	tgttcaagag	actggagaac	tatagccggt	ctcctttatt	ctccaccatc	1560
ctcaattctc	tgcaaggcct	gagctccatc	catgtctatg	gaaaaactga	agacttcatc	1620
agccag						1626

<210> 10  
 <211> 542  
 <212> PRT  
 <213> homo sapiens

<400> 10  
 Met Thr Arg Met Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser  
 1 5 10 15  
 Asp Gln Arg Ile Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu  
 20 25 30  
 Ile Lys Met Tyr Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp  
 35 40 45  
 Leu Arg Arg Lys Glu Arg Lys Leu Leu Glu Lys Cys Gly Leu Val Gln  
 50 55 60  
 Ser Leu Thr Ser Ile Thr Leu Phe Ile Ile Pro Thr Val Ala Thr Ala  
 65 70 75 80  
 Val Trp Val Leu Ile His Thr Ser Leu Lys Leu Thr Ala Ser  
 85 90 95  
 Met Ala Phe Ser Met Leu Ala Ser Leu Asn Leu Leu Arg Leu Ser Val  
 100 105 110  
 Phe Phe Val Pro Ile Ala Val Lys Gly Leu Thr Asn Ser Lys Ser Ala  
 115 120 125  
 Val Met Arg Phe Lys Lys Phe Phe Leu Gln Glu Ser Pro Val Phe Tyr  
 130 135 140  
 Val Gln Thr Leu Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala  
 145 150 155 160  
 Thr Leu Ser Trp Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu  
 165 170 175  
 Glu Leu Glu Arg Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg  
 180 185 190  
 Asp Ala Leu Gly Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu  
 195 200 205  
 His Lys Ile Asn Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys  
 210 215 220  
 Gly Asn Thr Gly Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu  
 225 230 235 240  
 Glu Met His Leu Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala  
 245 250 255  
 Tyr Val Pro Gln Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn

	260		265		270										
Ile	Leu	Met	Gly	Gly	Ala	Tyr	Asp	Lys	Ala	Arg	Tyr	Leu	Gln	Val	Leu
	275						280					285			
His	Cys	Cys	Ser	Leu	Asn	Arg	Asp	Leu	Glu	Leu	Leu	Pro	Phe	Gly	Asp
	290						295					300			
Met	Thr	Glu	Ile	Gly	Glu	Arg	Gly	Leu	Asn	Leu	Ser	Gly	Gly	Gln	Lys
	305						310					315			320
Gln	Arg	Ile	Ser	Leu	Ala	Arg	Ala	Val	Tyr	Ser	Asp	Arg	Gln	Ile	Tyr
							325								335
Leu	Leu	Asp	Asp	Pro	Leu	Ser	Ala	Val	Asp	Ala	His	Val	Gly	Lys	His
							340								350
Ile	Phe	Glu	Glu	Cys	Ile	Lys	Lys	Thr	Leu	Arg	Gly	Lys	Thr	Val	Val
							355								365
Leu	Val	Thr	His	Gln	Leu	Gln	Tyr	Leu	Glu	Phe	Cys	Gly	Gln	Ile	Ile
							370								380
Leu	Leu	Glu	Asn	Gly	Lys	Ile	Cys	Glu	Asn	Gly	Thr	His	Ser	Glu	Leu
							385								400
Met	Gln	Lys	Lys	Gly	Lys	Tyr	Ala	Gln	Leu	Ile	Gln	Lys	Met	His	Lys
							405								415
Glu	Ala	Thr	Ser	Val	Phe	Arg	Cys	Pro	Met	Ser	Phe	Phe	Asp	Thr	Ile
							420								430
Pro	Ile	Gly	Arg	Leu	Leu	Asn	Cys	Phe	Ala	Gly	Asp	Leu	Glu	Gln	Leu
							435								445
Asp	Gln	Leu	Leu	Pro	Ile	Phe	Ser	Glu	Gln	Phe	Leu	Val	Leu	Ser	Leu
							450								460
Met	Val	Ile	Ala	Val	Leu	Ile	Val	Ser	Val	Leu	Ser	Pro	Tyr	Ile	
							465								480
Leu	Leu	Met	Gly	Ala	Ile	Ile	Met	Val	Ile	Cys	Phe	Ile	Tyr	Tyr	Met
							470								485
Met	Phe	Lys	Lys	Ala	Ile	Gly	Val	Phe	Lys	Arg	Leu	Glu	Asn	Tyr	Ser
							500								510
Arg	Ser	Pro	Leu	Phe	Ser	His	Ile	Leu	Asn	Ser	Leu	Gln	Gly	Leu	Ser
							515								525
Ser	Ile	His	Val	Tyr	Gly	Lys	Thr	Glu	Asp	Phe	Ile	Ser	Gln		
							530								540

<210> 11  
 <211> 2700  
 <212> DNA  
 <213> homo sapiens

<400> 11	
atgacaagaa	tggtgtgtgaa
cggtgtgacca	gtgaagtctt
ccatttgc	aaatcattga
gggcttgctc	agagcctgac
tgctgggttc	tcctccacac
atgtgggctc	ccttgaatct
ggtctccaga	attccaagtc
cctgttttct	atgtccagac
acctgtctct	ggcaacagac
aacgggcatc	cttctgagg
gggaacagcc	tgggcccaga
ttagggttct	gcggaacac
gagatgcact	tgctcagg
caggcctgga	tcgtcagcgg
	ggctcagcat
	cacacatctg
	aggtcagcga
	ccagcgcatc
	60
	cggtgtgacca
	gtgaagtctt
	cacttgcatt
	aagctgatta
	aaatgtacac
	atgggagaaa
	120
	cgatttgc
	aaatcattga
	agacctga
	aggaaggaaa
	ggaagctatt
	ggagaagtgc
	180
	gggcttgctc
	agagcctgac
	aagtataacc
	ttgttcatca
	tccccacagt
	ggccacagcg
	240
	tgctgggttc
	tcctccacac
	atccttaaag
	ctgaaactca
	cagcgtcaat
	ggccttcagc
	300
	atgtgggctc
	ccttgaatct
	tcagtggtct
	tgctgcctat
	tcagctcaaa
	360
	ggtctccaga
	attccaagtc
	tgccagtcat
	aggctcaaga
	agtttttctc
	ccaggagagc
	420
	cctgttttct
	atgtccagac
	cccagcaaa
	ctctgttctt
	tgaggaggcc
	480
	acctgtctct
	ggcaacagac
	ctgtccggg
	atcgtcaatg
	gggactgga
	gctggagagg
	540
	aacgggcatc
	cttctgagg
	gatgaccagg
	cctagagatg
	ccctcgggcc
	agaggaaaga
	600
	gggaacagcc
	tgggcccaga
	gttgacaa
	atcaacctgg
	tggtgtccaa
	gggagatgat
	660
	ttagggttct
	gcggaacac
	ggggagtggt
	aagagcagcc
	tggtgtcagc
	catcctggag
	720
	gagatgcact
	tgctcagg
	ctcgggtggg
	gtgcagggaa
	ccctcgccca
	tgctccccag
	780
	caggcctgga
	tcgtcagcgg
	gaacatcagg
	gagaacatcc
	tcattggagg
	cgcattatgatc
	840

aagggccgat	acctccaggt	gctccactgc	tgtccctgta	atcgggagct	ggaactctgt	900
ccctttggag	acatgacaga	gattggagag	cggggcctca	acctctcttg	ggggcagaaa	960
cagaggatca	gcctggcccg	cgcgctctat	tcgacccgtc	agatctacct	gctggacgac	1020
ccctgtctgc	ctgtggagcg	ccacgtgggg	aagcacattt	ttgaggagtg	cattaagaag	1080
acctcaggg	ggaagacggt	cgtcctgggt	acccaccagc	tgcagtaact	agaattttgt	1140
ggccagatca	ttttgttgga	aaatgggaaa	atctgtgaaa	atggaactca	cagtgtagta	1200
atcgagaaaa	aggggaaata	tgcccaactt	atccagaaga	tgacacaagg	agccactctg	1260
gtttttccgt	gcgccatgag	tttttttgac	accatcccaa	tagggccggt	tttgaactgc	1320
ttcgacgggg	acttgggaaca	gctggaccag	ctcttgccca	tcttttcaga	gcagttctctg	1380
gtcctgtcct	taattggtgat	cgcgctcctg	ttgattgtca	gtgtgctgtc	tccatatatc	1440
ctgttaattg	gagccataat	catggttatt	tgcttctatt	attatatgat	gttcaagaag	1500
gccatcggtg	gtttcaagag	actggagaac	tatagccggt	ctcctttatt	ctccaccatc	1560
ctcaattctc	tgcaaggcct	gagctccatc	catgtctatg	gaaaaactga	agacttcatc	1620
agccagttta	agaggctgac	tgatgcgcag	aataactacc	tgctgttggt	tctatcttcc	1680
acacgatgga	tggcattgag	gctggagatc	atgaccaacc	ttgtgacctt	ggctgttgcc	1740
ctgttcctgg	cttttggcat	ttctccacc	ccctactcct	ttaaagtcat	ggctgtcaac	1800
atcgtgtcgc	agctggcgct	cagcttccag	gccactgcc	ggattgtgct	ggagacagag	1860
gcacagttca	cggctgtaga	gaggatactg	cagtacatga	agatgtgtgt	ctcgggaagct	1920
ctttatcaca	tggaaaggcac	aagtgttccc	caggggtggc	cacagcatgg	ggaaatcata	1980
tttcagagatt	atcacatgaa	atacagagac	aacacaccca	ccgtgcttca	cggcatcaac	2040
ctgaccatcc	cgccgacaga	agtggtgggc	atcgtgggaa	ggacgggctc	tgggaagtec	2100
tccttgggca	tggctctctt	ccgcttggtg	gagcccatgg	caggccggat	tctcattgac	2160
ggcgtggaca	tttgacgcat	cggcctggag	gacttgcggt	ccaagctctc	agtgatccct	2220
caagatccag	tgctgtcttc	aggaaccatc	agattcaacc	tagatccctt	tgaccgtcac	2280
actgaccagc	agatctggga	tgcttgggag	aggacattcc	tgaccaaggc	catctcaaac	2340
ttccccaaaa	agctgcatac	agatgtgggt	gaaaacgggt	gaaactcttc	tgtgggggag	2400
aggcagctgc	tctgcatttc	cagggctgtg	cttcgcaact	ccaagatcat	ccttatcgat	2460
gaagccacag	ctccatttga	catggagaca	gacaccccta	tcacgcgcac	aatccgtgaa	2520
gcccttcagg	ctgcaccgtg	gctgtcatt	gccaccggt	tcaccactgt	gctgaactgt	2580
gaccacatcc	tgggttatgg	caatgggaag	gtggtagaat	ttgatcgccc	ggaggtactg	2640
cggagaaga	ctgggtcatt	gttcgcagcc	ctcatggcca	cagccacttc	ttcactgaga	2700

<210> 12

<211> 900

<212> PRT

<213> homo sapiens

<400> 12

Met	Thr	Arg	Met	Ala	Val	Lys	Ala	Gln	His	His	Thr	Ser	Glu	Val	Ser
1				5				10					15		
Asp	Gln	Arg	Ile	Arg	Val	Thr	Ser	Glu	Val	Leu	Thr	Cys	Ile	Lys	Leu
			20					25					30		
Ile	Lys	Met	Tyr	Thr	Trp	Glu	Lys	Pro	Phe	Ala	Lys	Ile	Ile	Glu	Asp
			35				40					45			
Leu	Arg	Arg	Lys	Glu	Arg	Lys	Leu	Leu	Glu	Lys	Cys	Gly	Leu	Val	Gln
	50				55					60					
Ser	Leu	Thr	Ser	Ile	Thr	Leu	Phe	Ile	Ile	Pro	Thr	Val	Ala	Thr	Ala
65				70						75				80	
Val	Trp	Val	Leu	Ile	His	Thr	Ser	Leu	Lys	Leu	Lys	Leu	Thr	Ala	Ser
			85					90					95		
Met	Ala	Phe	Ser	Met	Leu	Ala	Ser	Leu	Asn	Leu	Leu	Arg	Leu	Ser	Val
			100				105						110		
Phe	Phe	Val	Pro	Ile	Ala	Val	Lys	Gly	Leu	Thr	Asn	Ser	Lys	Ser	Ala
			115				120						125		
Val	Met	Arg	Phe	Lys	Lys	Phe	Phe	Leu	Gln	Glu	Ser	Pro	Val	Phe	Tyr
	130					135					140				

Val Gln Thr Leu Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala  
 145 150 155 160  
 Thr Leu Ser Trp Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu  
 165 170 175  
 Glu Leu Glu Arg Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg  
 180 185 190  
 Asp Ala Leu Gly Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu  
 195 200 205  
 His Lys Ile Asn Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys  
 210 215 220  
 Gly Asn Thr Gly Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu  
 225 230 235 240  
 Glu Met His Leu Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala  
 245 250 255  
 Tyr Val Pro Gln Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn  
 260 265 270  
 Ile Leu Met Gly Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu  
 275 280 285  
 His Cys Cys Ser Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp  
 290 295 300  
 Met Thr Glu Ile Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys  
 305 310 315 320  
 Gln Arg Ile Ser Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr  
 325 330 335  
 Leu Leu Asp Asp Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His  
 340 345 350  
 Ile Phe Glu Glu Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val  
 355 360 365  
 Leu Val Thr His Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile  
 370 375 380  
 Leu Leu Glu Asn Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu  
 385 390 395 400  
 Met Gln Lys Lys Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys  
 405 410 415  
 Glu Ala Thr Ser Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile  
 420 425 430  
 Pro Ile Gly Arg Leu Leu Asn Cys Phe Ala Gly Asp Leu Glu Gln Leu  
 435 440 445  
 Asp Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val Leu Ser Leu  
 450 455 460  
 Met Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile  
 465 470 475 480  
 Leu Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met  
 485 490 495  
 Met Phe Lys Lys Ala Ile Gly Val Phe Lys Arg Leu Glu Asn Tyr Ser  
 500 505 510  
 Arg Ser Pro Leu Phe Ser His Ile Leu Asn Ser Leu Gln Gly Leu Ser  
 515 520 525  
 Ser Ile His Val Tyr Gly Lys Thr Glu Asp Phe Ile Ser Gln Phe Lys  
 530 535 540  
 Arg Leu Thr Asp Ala Gln Asn Asn Tyr Leu Leu Leu Phe Leu Ser Ser  
 545 550 555 560  
 Thr Arg Trp Met Ala Leu Arg Leu Glu Ile Met Thr Asn Leu Val Thr  
 565 570 575  
 Leu Ala Val Ala Leu Phe Val Ala Phe Gly Ile Ser Ser Thr Pro Tyr  
 580 585 590

Ser Phe Lys Val Met Ala Val Asn Ile Val Leu Gln Leu Ala Ser Ser  
 595 600 605  
 Phe Gln Ala Thr Ala Arg Ile Gly Leu Glu Thr Glu Ala Gln Phe Thr  
 610 615 620  
 Ala Val Glu Arg Ile Leu Gln Tyr Met Lys Met Cys Val Ser Glu Ala  
 625 630 635 640  
 Pro Leu His Met Glu Gly Thr Ser Cys Pro Gln Gly Trp Pro Gln His  
 645 650 655  
 Gly Glu Ile Ile Phe Gln Asp Tyr His Met Lys Tyr Arg Asp Asn Thr  
 660 665 670  
 Pro Thr Val Leu His Gly Ile Asn Leu Thr Ile Arg Gly His Glu Val  
 675 680 685  
 Val Gly Ile Val Gly Arg Thr Gly Ser Gly Lys Ser Ser Leu Gly Met  
 690 695 700  
 Ala Leu Phe Arg Leu Val Glu Pro Met Ala Gly Arg Ile Leu Ile Asp  
 705 710 715 720  
 Gly Val Asp Ile Cys Ser Ile Gly Leu Glu Asp Leu Arg Ser Lys Leu  
 725 730 735  
 Ser Val Ile Pro Gln Asp Pro Val Leu Leu Ser Gly Thr Ile Arg Phe  
 740 745 750  
 Asn Leu Asp Pro Phe Asp Arg His Thr Asp Gln Gln Ile Trp Asp Ala  
 755 760 765  
 Leu Glu Arg Thr Phe Leu Thr Lys Ala Ile Ser Lys Phe Pro Lys Lys  
 770 775 780  
 Leu His Thr Asp Val Val Glu Asn Gly Gly Asn Phe Ser Val Gly Glu  
 785 790 795 800  
 Arg Gln Leu Leu Cys Ile Ala Arg Ala Val Leu Arg Asn Ser Lys Ile  
 805 810 815  
 Ile Leu Ile Asp Glu Ala Thr Ala Ser Ile Asp Met Glu Thr Asp Thr  
 820 825 830  
 Leu Ile Gln Arg Thr Ile Arg Glu Ala Phe Gln Gly Cys Thr Val Leu  
 835 840 845  
 Val Ile Ala His Arg Val Thr Thr Val Leu Asn Cys Asp His Ile Leu  
 850 855 860  
 Val Met Gly Asn Gly Lys Val Val Glu Phe Asp Arg Pro Glu Val Leu  
 865 870 875 880  
 Arg Lys Lys Pro Gly Ser Leu Phe Ala Ala Leu Met Ala Thr Ala Thr  
 885 890 895  
 Ser Ser Leu Arg  
 900

<210> 13

<211> 2937

<212> DNA

<213> homo sapiens

<400> 13

atgactagga	agaggacata	ctgggtgcc	aactcttctg	gtggcctcgt	gaatcgtggc	60
atcgacatag	gcgatgacat	ggtttcagga	cttattttata	aaacctatac	ttcccaagat	120
ggccctcgga	gtcagcaaga	gagaaatcct	gaggctccag	ggaggggcagc	tgccccaccg	180
tgggggaagt	atgatgctgc	cttgagaacc	atgattccct	tcggtcccaa	gcgaggtttt	240
ctgtcccccc	agccccctgga	caatgctggc	ctgtttctct	acctcaccgt	gcatgggctc	300
accgccctca	tgatccaaag	cttacggagt	cgcttagatg	agaacaccat	ccctccactg	360
tcagtccatg	atgcctcaga	caaaaatgtc	caagggtctc	accgcctttg	ggaagaagaa	420
gtctcaaggc	gagggattga	aaaagcttca	gtgcttctgg	tgatgctgag	gttccagaga	480
acaagggtga	ttttcgatgc	acttctgggc	atctgcttct	gcattgccag	tgtactcggg	540

ccaatatgga ttataccaaa gatcctggaa tattcagaag agcagttggg gaatgtgtgc 600  
 catggagttg gactctgtct tgcctctttt ctctccgaat gtgtgaagtc tctgagtttc 660  
 tctccagatt ggatcatcaa ccaacgcaca gccatcagggt tccaagcaga tgtttcctcc 720  
 tttgcctttg agaagctcat ccaatttaag tctgtaatac acatcaccct aggagagggc 780  
 atcagctttct tcacgggtga tgtaaactac ctgtttgaag ggggtgtgcta tggaccctta 840  
 gtactgatca ctgtgcgcat gctggctcat tgcagcattt ctctctactt catatttgga 900  
 tacactgcat ttattgcat ctatgtctat ctctctgttt tccacttgga ggtattcatg 960  
 acaagaattg ctgtgaaggc tcagcatcac acatctgagg tcacgcacca gcgcattccgt 1020  
 gtgcacaggg aagttctctc ttgcattaaag ctgattaaaa tgtacacatg ggagaaacca 1080  
 ttcaaaaaaa tcattgaaaga cctaagaagg aaggaaagga agctatttga gaagtgcagg 1140  
 cttgtccaga gcctgacaag tataaccttg ttcattatcc ccacagtggt cacagcggtc 1200  
 tgggtttctca tccacacatc cttaaaagctg aaactcacag cgtcaatggc cttcagcatg 1260  
 ctggcctcct tgaattctct tggcgtgtca gtgttctttg tgcctattgc agtcaaaagg 1320  
 ctacagaatt ccaagtctgc agtgatgagg ttcaagaagt ttttctccca ggagagccct 1380  
 gttttctatg tccagacatt acaagacccc agcaaaagctc tggctcttga ggaggccacc 1440  
 ttgtcatggc aacagacctg tcccggggtc gtcaatgggg cactggagct ggagaggaaac 1500  
 gggcatgctt ctgagggggt gaccaggcct agagatgccc tccggggcaga ggaagaaggg 1560  
 aacagcctgt gccacaggtt gcacaagatc aaactggtgg tgtccaaagg gatgatgtta 1620  
 ggggtctcgc gcaacacggg gagtggtaag agcagcctgt tgtcagccat cctggaggag 1680  
 atgcacttgc tgcagggggt ggtgggggtg cagggaagcc tggcctatgt cccccagag 1740  
 gcttgatgc tcacggggaa catcaggggg aacatcctca tggggaggcg atatgacaag 1800  
 gcccgatacc tccaggtgct ccaactgtgc tccctgaatc gggacctgga actctgtccc 1860  
 tttggagaca tgacagagat tggagagcgg ggcctcaacc tctctggggg gcagaacacg 1920  
 aggatcagcc tggcccgccg cgtctattcc gaccgtcaga tctacctgtc ggacgacccc 1980  
 ctgtctcttg tggacgccca cgtggggaag cacatttttg aggagtgcgt taagaagaca 2040  
 ctacagggga agacgggtgt cctggtgacc caccagctgc agtacttaga attttgtggc 2100  
 cagatcattt tgttggaaaa tgggaaaaatc tgtgaaaaat gaactcacg tgaagttaag 2160  
 cagaaaaagg ggaatatatgc ccaacttatt cagaagatgc acaaggaaag cacttcggac 2220  
 atgttgcagg acacagcaaa gatagcagag aagccaaagg tagaaagtca ggctctggcc 2280  
 acctcccggt aagagtctct caacggaaat gctgtgcggg agcatcagct cacacagagc 2340  
 gaggagatgg aagaaggctc cttagtttgg agggctatcc accactacat ccaggcagct 2400  
 ggagggttaca tggctctctg cataatttct tctctgttgg tctgtatcgt cttcttaacg 2460  
 atcttcagct tctggtggtc gactactagg ttggagcagg gctcggggac caatagcagc 2520  
 cgagagagca atggaaccat ggcagacctg ggcaacattg cagacaatcc tcaactgtcc 2580  
 ttctaccagg tgggtgacgg gctcaacgcc ctgctctcca tctgtgtggg ggtctgtccc 2640  
 tcagggtatt tcaccaaggt cacgaggaag gcattccagg ccctgcacaa caagctcttc 2700  
 aacaaggttt tccgctgccc catgagtttc ttgacacca tcccaatagg ccggcttttg 2760  
 aactgcttcg caggggacct ggaacagctg gaccagctct tgcccatctt ttcagagcag 2820  
 ttctgggtcc tgtccttaat ggtgatcgcc gtcctgttga ttgtcagttg gctgtctcca 2880  
 tatatcctgt taatgggagc cataatcatg gttatttgc tcatattatta tatgtga 2937

<210> 14  
 <211> 975  
 <212> PRT  
 <213> homo sapiens

<400> 14  
 Met Thr Arg Lys Arg Thr Tyr Trp Val Pro Asn Ser Ser Gly Gly Leu  
 1 5 10 15  
 Val Asn Arg Gly Ile Asp Ile Gly Asp Asp Met Val Ser Gly Leu Ile  
 20 25 30  
 Tyr Lys Thr Tyr Thr Leu Gln Asp Gly Pro Trp Ser Gln Gln Glu Arg  
 35 40 45  
 Asn Pro Glu Ala Pro Gly Arg Ala Ala Val Pro Pro Trp Gly Lys Tyr  
 50 55 60  
 Asp Ala Ala Leu Arg Thr Met Ile Pro Phe Arg Pro Lys Pro Arg Phe

65	70	75	80
Pro Ala Pro Gln Pro Leu Gly Leu Phe Ser Tyr Leu Thr Val Ser Trp			
	85	90	95
Leu Thr Pro Leu Met Ile Gln Ser Leu Arg Ser Arg Leu Asp Glu Asn			
	100	105	110
Thr Ile Pro Pro Leu Ser Val His Asp Ala Ser Asp Lys Asn Val Gln			
	115	120	125
Arg Leu His Arg Leu Trp Glu Glu Val Ser Arg Arg Gly Ile Glu			
	130	135	140
Lys Ala Ser Val Leu Leu Val Met Leu Arg Phe Gln Arg Thr Arg Leu			
	145	150	155
Ile Phe Asp Ala Leu Leu Gly Ile Cys Phe Cys Ile Ala Ser Val Leu			
	165	170	175
Gly Pro Ile Leu Ile Ile Pro Lys Ile Leu Glu Tyr Ser Glu Glu Gln			
	180	185	190
Leu Gly Asn Val Val His Gly Val Gly Leu Cys Phe Ala Leu Phe Leu			
	195	200	205
Ser Glu Cys Val Lys Ser Leu Ser Phe Ser Ser Ser Trp Ile Ile Asn			
	210	215	220
Gln Arg Thr Ala Ile Arg Phe Gln Ala Ala Val Ser Ser Phe Ala Phe			
	225	230	235
Glu Lys Leu Ile Gln Phe Lys Ser Val Ile His Ile Thr Ser Gly Glu			
	245	250	255
Ala Ile Ser Phe Phe Thr Gly Asp Val Asn Tyr Leu Phe Glu Gly Val			
	260	265	270
Cys Tyr Gly Pro Leu Val Leu Ile Thr Cys Ala Ser Leu Val Ile Cys			
	275	280	285
Ser Ile Ser Ser Tyr Phe Ile Ile Gly Tyr Thr Ala Phe Ile Ala Ile			
	290	295	300
Leu Cys Tyr Leu Leu Val Phe Pro Leu Glu Val Phe Met Thr Arg Met			
	305	310	315
Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser Asp Gln Arg Ile			
	325	330	335
Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu Ile Lys Met Tyr			
	340	345	350
Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp Leu Arg Arg Lys			
	355	360	365
Glu Arg Lys Leu Leu Glu Lys Cys Gly Leu Val Gln Ser Leu Thr Ser			
	370	375	380
Ile Thr Leu Phe Ile Ile Pro Thr Val Ala Thr Ala Val Trp Val Leu			
	385	390	395
Ile His Thr Ser Leu Lys Leu Lys Leu Thr Ala Ser Met Ala Phe Ser			
	405	410	415
Met Leu Ala Ser Leu Asn Leu Leu Arg Leu Ser Val Phe Phe Val Pro			
	420	425	430
Ile Ala Val Lys Gly Leu Thr Asn Ser Lys Ser Ala Val Met Arg Phe			
	435	440	445
Lys Lys Phe Phe Leu Gln Glu Ser Pro Val Phe Tyr Val Gln Thr Leu			
	450	455	460
Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala Thr Leu Ser Trp			
	465	470	475
Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu Glu Leu Glu Arg			
	485	490	495
Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg Asp Ala Leu Gly			
	500	505	510
Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu His Lys Ile Asn			



515                      520                      525  
 Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys Gly Asn Thr Gly  
 530                      535                      540  
 Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu Glu Met His Leu  
 545                      550                      555                      560  
 Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala Tyr Val Pro Gln  
 565                      570                      575  
 Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn Ile Leu Met Gly  
 580                      585                      590  
 Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu His Cys Cys Ser  
 595                      600                      605  
 Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp Met Thr Glu Ile  
 610                      615                      620  
 Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys Gln Arg Ile Ser  
 625                      630                      635                      640  
 Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr Leu Leu Asp Asp  
 645                      650                      655  
 Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His Ile Phe Glu Glu  
 660                      665                      670  
 Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val Leu Val Thr His  
 675                      680                      685  
 Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile Leu Leu Glu Asn  
 690                      695                      700  
 Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu Met Gln Lys Lys  
 705                      710                      715                      720  
 Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys Glu Ala Thr Ser  
 725                      730                      735  
 Asp Met Leu Gln Asp Thr Ala Lys Ile Ala Glu Lys Pro Lys Val Glu  
 740                      745                      750  
 Ser Gln Ala Leu Ala Thr Ser Leu Glu Glu Ser Leu Asn Gly Asn Ala  
 755                      760                      765  
 Val Pro Glu His Gln Leu Thr Gln Glu Glu Met Glu Glu Gly Ser  
 770                      775                      780  
 Leu Ser Trp Arg Val Tyr His His Tyr Ile Gln Ala Ala Gly Gly Tyr  
 785                      790                      795                      800  
 Met Val Ser Cys Ile Ile Phe Phe Phe Val Val Leu Ile Val Phe Leu  
 805                      810                      815  
 Thr Ile Phe Ser Phe Trp Trp Leu Ser Tyr Trp Leu Glu Gln Gly Ser  
 820                      825                      830  
 Gly Thr Asn Ser Ser Arg Glu Ser Asn Gly Thr Met Ala Asp Leu Gly  
 835                      840                      845  
 Asn Ile Ala Asp Asn Pro Gln Leu Ser Phe Tyr Gln Leu Val Tyr Gly  
 850                      855                      860  
 Leu Asn Ala Leu Leu Leu Ile Cys Val Gly Val Cys Ser Ser Gly Ile  
 865                      870                      875                      880  
 Phe Thr Lys Val Thr Arg Lys Ala Ser Thr Ala Leu His Asn Lys Leu  
 885                      890                      895  
 Phe Asn Lys Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile Pro  
 900                      905                      910  
 Ile Gly Arg Leu Leu Asn Cys Phe Ala Gly Asp Leu Glu Gln Leu Asp  
 915                      920                      925  
 Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val Leu Ser Leu Met  
 930                      935                      940  
 Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile Leu  
 945                      950                      955                      960  
 Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met

<210> 15  
 <211> 3075  
 <212> DNA  
 <213> homo sapiens

<400> 15

atgactagga	agaggacata	ctgggtgccc	aactctctctg	gtggcctcgt	gaatcgtggc	60
atcgacatag	gcgatgacat	ggtttccagga	cttatttata	aaacctatac	tctccaagat	120
ggccccctgga	gtcagacaaga	gagaaatcct	gaggtccacg	ggaggggcagc	tgtcccaccg	180
tgggggaagt	atgatgtctgc	cttgagaace	atgattccct	tccgtcccaa	gcgcagggttt	240
cctgcccccc	agcccttggg	caatgctggc	ctgtttctct	acctcacctg	gtcatggctc	300
accocgctca	tgatccaaag	cttacggagt	cgcttagatg	agaacacccat	ccctccactg	360
tcagtccatg	atgcctcaga	caaaaatgtc	caaaggcttc	accgcctttg	ggaagaagaa	420
gtctcaaggc	gagggattga	aaaagcttca	gtgcttctgg	tgatgctgag	gttccagaga	480
acaaggttga	ttttcgatgc	acttctgggc	atctgcttct	gcattgccag	tgactctggg	540
ccaatatgga	ttataccaaa	gatcctggaa	tattcagaag	agcagttggg	gaatgtgtgc	600
catggagtgg	gactctgctt	tgcccttttt	ctctccgaat	gtgtgaagtc	tctgagtttc	660
tctctcagtt	ggatcatcaa	ccaacgcaca	gccatcaggt	tccaagcagc	tgtttctccc	720
tttgctcttg	agaagctcat	ccaatttaag	tctgtaatac	acatcacctc	aggagagggc	780
atcagcttct	tcacccgtga	tgtaaaactac	ctgtttgaag	gggtgtgcta	tggaccccta	840
gtactgtaca	cctgcgcatc	gctggctcatc	tgacagcttt	cttctacttt	cattatttga	900
tacactgcat	ttattgcatc	cttatgctat	ctcctgggtt	tcccacttga	ggatattcatg	960
acaagaatgg	ctgtgaaggg	tcagcatcac	acatctgagg	tcagcgacca	gcgcctccgt	1020
gtgacagctg	aagttctcac	ttgcattaag	ctgattaaaa	tgtaacacat	ggagaaacca	1080
tttgcacaaa	tcattgaaga	cctaagaagg	aaggaaagga	agctatttga	gaatgctggg	1140
cttgtccaga	gcctgacaag	tataaccttg	ttcatcatcc	ccacagtggc	cacagcggtc	1200
tgggtttcca	tcacacatca	cttaaaagct	aaactcacag	cgctcaatggc	cttcacagctg	1260
ctggcctcct	tgaattctct	tcggctgtca	gtgttctttg	tgccatttgc	agtcacaagg	1320
ctcacaagtt	ccaagtctgc	agtgatgagg	ttcaagaagt	ttttctcca	ggagagccct	1380
gttttctatg	tcacagacatt	acaagacccc	agcaagctc	tggtctttga	ggagccaccc	1440
ttgtcatggc	aacagacctg	tcccgggatac	gtcaatgggg	cactggagct	ggagaggaac	1500
gggcatgctt	ctgaggggat	gaccaggcct	agagatgccc	ctgggcccaga	ggaagaaggg	1560
aaacgcctgg	gcccagagtt	gcacaagatc	aaactgtgtg	tgtccaaggg	gatgatgtta	1620
gggtctctgc	gcaaacccgg	gagtggttaag	agcagcctgt	tgctcagcat	cctggaggag	1680
atgcacttgc	tcaggggctc	ctgaggggtg	cagggaagcc	tgccctatgt	ccccagcag	1740
gcctggatgc	tcagccggaa	catcagggag	aaactctca	tgggagggcg	atatgacaag	1800
gcccagatcc	tccagtgctc	ccactgctgc	tccttgaaic	gggaccttga	agcttctccc	1860
tttgagagaca	tgacagagat	tggagagcgg	ggcctcaacc	tctctggggg	gcagaaacag	1920
aggatcagcc	tggcccgctc	cgctattctc	gacccgtcaga	ttacactgct	ggacgacccc	1980
ctgtctctgt	tggacgccc	cgctggggaag	cacatttttg	aggagtgcat	taagaagaca	2040
ctcagggggg	agacggtcgt	cctgtgtgacc	caccagctgc	agtacttaga	attttgtggc	2100
cagatcattt	tgttggaata	tgggaaatac	tgtaaaaatg	gaactcacac	tgagtttaag	2160
cagaaaaagg	ggaaaatatgc	ccaactatc	cagaagatgc	acaaggaaag	caactctggac	2220
atgttgcagg	acacagcaaa	gatagcagag	aagccaaaag	tagaaagtc	ggctctggcc	2280
acctcctctg	aagagttctc	caacggaaat	gctgtgcccg	agcatcagct	cacacagagc	2340
gaggagatgg	aagaaggctc	cttgagttgg	agggctctacc	accactacat	ccaggcagct	2400
ggagggttaca	tggtctcttg	cataattttc	ttctctgtgg	tgctgatctg	cttctttaaag	2460
atcttctagct	tctgtgtgct	gagctactgg	tggagcagg	gctcggggac	caatagcagc	2520
cgagagagca	atggaaccat	ggcagacctg	ggcaaacatc	cagacaactc	tcaactgtcc	2580
tctaccagc	tggtgtacgg	gctcaacgcc	ctgctctcca	tctgtgtggg	ggctctgtcc	2640
tcagggaatt	tcaccaaggt	cacaggaag	gctccacagg	ccctgcacaa	caagctcttc	2700
aaacaagttt	tccgctgccc	catgagtttc	tttgacacca	tcccataagg	ccggtttttg	2760
aactgcttgc	caggggactt	ggaacagctg	gaccagctct	tgccactctt	ttcagagcag	2820
ttctctgtcc	tgctcctaat	ggtgatcgcc	gtcctgttga	ttgtcagttg	gctgtctcca	2880

tatatcctgt taatgggagc cataatcatg gttatttgct tcatttatta tatgatgttc 2940  
aagaaggcca tcgggtgtgt caagagactg gagaactata gccggctccc tttattctcc 3000  
cacatctcta attctctgca aggcctgagc tccatccatg tctatggaaa aactgaagac 3060  
ttcatcagcc agtga 3075

<210> 16  
<211> 1021  
<212> PRT  
<213> homo sapiens

<400> 16  
Met Thr Arg Lys Arg Thr Tyr Trp Val Pro Asn Ser Ser Gly Gly Leu  
1 5 10 15  
Val Asn Arg Gly Ile Asp Ile Gly Asp Met Val Ser Gly Leu Ile  
20 25 30  
Tyr Lys Thr Tyr Thr Leu Gln Asp Gly Pro Trp Ser Gln Gln Glu Arg  
35 40 45  
Asn Pro Glu Ala Pro Gly Arg Ala Ala Val Pro Pro Trp Gly Lys Tyr  
50 55 60  
Asp Ala Ala Leu Arg Thr Met Ile Pro Phe Arg Pro Lys Pro Arg Phe  
65 70 75 80  
Pro Ala Pro Gln Pro Leu Gly Leu Phe Ser Tyr Leu Thr Val Ser Trp  
85 90 95  
Leu Thr Pro Leu Met Ile Gln Ser Leu Arg Ser Arg Leu Asp Glu Asn  
100 105 110  
Thr Ile Pro Pro Leu Ser Val His Asp Ala Ser Asp Lys Asn Val Gln  
115 120 125  
Arg Leu His Arg Leu Trp Glu Glu Val Ser Arg Arg Gly Ile Glu  
130 135 140  
Lys Ala Ser Val Leu Leu Val Met Leu Arg Phe Gln Arg Thr Arg Leu  
145 150 155 160  
Ile Phe Asp Ala Leu Leu Gly Ile Cys Phe Cys Ile Ala Ser Val Leu  
165 170 175  
Gly Pro Ile Leu Ile Ile Pro Lys Ile Leu Glu Tyr Ser Glu Glu Gln  
180 185 190  
Leu Gly Asn Val Val His Gly Val Gly Leu Cys Phe Ala Leu Phe Leu  
195 200 205  
Ser Glu Cys Val Lys Ser Leu Ser Phe Ser Ser Ser Trp Ile Ile Asn  
210 215 220  
Gln Arg Thr Ala Ile Arg Phe Gln Ala Ala Val Ser Ser Phe Ala Phe  
225 230 235 240  
Glu Lys Leu Ile Gln Phe Lys Ser Val Ile His Ile Thr Ser Gly Glu  
245 250 255  
Ala Ile Ser Phe Phe Thr Gly Asp Val Asn Tyr Leu Phe Glu Gly Val  
260 265 270  
Cys Tyr Gly Pro Leu Val Leu Ile Thr Cys Ala Ser Leu Val Ile Cys  
275 280 285  
Ser Ile Ser Ser Tyr Phe Ile Ile Gly Tyr Thr Ala Phe Ile Ala Ile  
290 295 300  
Leu Cys Tyr Leu Leu Val Phe Pro Leu Glu Val Phe Met Thr Arg Met  
305 310 315 320  
Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser Asp Gln Arg Ile  
325 330 335  
Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu Ile Lys Met Tyr  
340 345 350  
Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp Leu Arg Arg Lys

355	360	365
Glu Arg Lys Leu Leu Glu Lys Cys Gly Leu Val Gln Ser Leu Thr Ser		
370	375	380
Ile Thr Leu Phe Ile Ile Pro Thr Val Ala Thr Ala Val Trp Val Leu		
385	390	395
Ile His Thr Ser Leu Lys Leu Lys Leu Thr Ala Ser Met Ala Phe Ser		
405	410	415
Met Leu Ala Ser Leu Asn Leu Leu Arg Leu Ser Val Phe Phe Val Pro		
420	425	430
Ile Ala Val Lys Gly Leu Thr Asn Ser Lys Ser Ala Val Met Arg Phe		
435	440	445
Lys Lys Phe Phe Leu Gln Glu Ser Pro Val Phe Tyr Val Gln Thr Leu		
450	455	460
Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala Thr Leu Ser Trp		
465	470	475
Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu Glu Leu Glu Arg		
485	490	495
Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg Asp Ala Leu Gly		
500	505	510
Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu His Lys Ile Asn		
515	520	525
Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys Gly Asn Thr Gly		
530	535	540
Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu Glu Met His Leu		
545	550	555
Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala Tyr Val Pro Gln		
565	570	575
Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn Ile Leu Met Gly		
580	585	590
Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu His Cys Cys Ser		
595	600	605
Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp Met Thr Glu Ile		
610	615	620
Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys Gln Arg Ile Ser		
625	630	635
Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr Leu Leu Asp Asp		
645	650	655
Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His Ile Phe Glu Glu		
660	665	670
Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val Leu Val Thr His		
675	680	685
Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile Leu Leu Glu Asn		
690	695	700
Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu Met Gln Lys Lys		
705	710	715
Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys Glu Ala Thr Ser		
725	730	735
Asp Met Leu Gln Asp Thr Ala Lys Ile Ala Glu Lys Pro Lys Val Glu		
740	745	750
Ser Gln Ala Leu Ala Thr Ser Leu Glu Glu Ser Leu Asn Gly Asn Ala		
755	760	765
Val Pro Glu His Gln Leu Thr Gln Glu Glu Glu Met Glu Glu Gly Ser		
770	775	780
Leu Ser Trp Arg Val Tyr His His Tyr Ile Gln Ala Ala Gly Gly Tyr		
785	790	795
Met Val Ser Cys Ile Ile Phe Phe Phe Val Val Leu Ile Val Phe Leu		
		800

805 810 815  
 Thr Ile Phe Ser Phe Trp Trp Leu Ser Tyr Trp Leu Glu Gln Gly Ser  
 820 825 830  
 Gly Thr Asn Ser Ser Arg Glu Ser Asn Gly Thr Met Ala Asp Leu Gly  
 835 840 845  
 Asn Ile Ala Asp Asn Pro Gln Leu Ser Phe Tyr Gln Leu Val Tyr Gly  
 850 855 860  
 Leu Asn Ala Leu Leu Leu Ile Cys Val Gly Val Cys Ser Ser Gly Ile  
 865 870 875 880  
 Phe Thr Lys Val Thr Arg Lys Ala Ser Thr Ala Leu His Asn Lys Leu  
 885 890 895  
 Phe Asn Lys Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile Pro  
 900 905 910  
 Ile Gly Arg Leu Leu Asn Cys Phe Ala Gly Asp Leu Glu Gln Leu Asp  
 915 920 925  
 Gln Leu Leu Pro Ile Phe Ser Glu Gln Phe Leu Val Leu Ser Leu Met  
 930 935 940  
 Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile Leu  
 945 950 955 960  
 Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met Met  
 965 970 975  
 Phe Lys Lys Ala Ile Gly Val Phe Lys Arg Leu Glu Asn Tyr Ser Arg  
 980 985 990  
 Ser Pro Leu Phe Ser His Ile Leu Asn Ser Leu Gln Gly Leu Ser Ser  
 995 1000 1005  
 Ile His Val Tyr Gly Lys Thr Glu Asp Phe Ile Ser Gln  
 1010 1015 1020

<210> 17  
 <211> 4149  
 <212> DNA  
 <213> homo sapiens

<400> 17  
 atgactagga agaggacata ctgggtgcc aactcttctg gtggcctcgt gaatcgtggc 60  
 atcgacatag gcgatgacat ggtttcagga cttatttata aaacctatac tctccaagat 120  
 ggccccctgga gtcagcaaga gagaaatcct gaggctccag ggagggcagc tgtcccacgc 180  
 tgggggaagt atgatctgctg cttgagaacc atgattccct tccgtcccaa gccgaggttt 240  
 cctgcccccc agccccctgga caatgctggc ctgttctcct acctcacgtg tgcattcgctc 300  
 accccgctca tgatccaaag cttacggagt cgcttagatg agaaccacat cctccactg 360  
 tcagtccatg atgcctcaga caaaaatgtc caaaggcttc accgccttg ggaagaagaa 420  
 gtctcaaggc gagggattga aaaaagctta gtgcttctgg tgatgctgag gtccagaga 480  
 acaaggttga ttttcgatgc acttctgggc atctgtctct gcattgccag tgtactcggg 540  
 coaatattga ttataccaaa gatctcgaa tattcagaag agcagttggg gaatgttgc 600  
 catggagtgg gactctgctt tgcccttttt ctctccgaat gtgtgaagtc tctgactctc 660  
 tctctccatg ggatcatcaa ccaacgcaca gccatcaggt tccaagcagc tgtttctctc 720  
 tttgcctttg agaagctcat ccaatttaag tctgtaatac acatcacctc aggagagggc 780  
 atcagcttct tcaccggtga gttaaactac ctgtttgaag ggggtgtgcta tggaccctga 840  
 gtaactgatca cctgcgcacg gctggtctac tgcagcattt ctctctactt cattattgga 900  
 tacactgcat ttattgccat cttatgctat ctctcgtttt tcccactgga ggtattcatg 960  
 acaagaatgg cttggaaggc tcagcatcac acatctgagg tcagcgacca gcgcattcgt 1020  
 gtgaccagtg aagtctcac ttgcattaag ctgattaaaa tgtacacatg ggagaacca 1080  
 ttgcaaaaaa tcattgaaga cctaagaagg aaggaaaagg agctattgga gaagtgcggg 1140  
 cttgtccaga gcccgacaag tataaccttg ttcacatcc cccagctggc cacagcggtc 1200  
 tgggttctca tccacacct cttaaagctg aaactcacag cgtcaatggc cttcagcatg 1260  
 ctggcctcct tgaattctct tcggctgtca gtgttctttg tgctattgc agtcaaaagg 1320

ctcacgaatt	ccaagtctgc	agtgatgagg	ttcaagaagt	ttttctctca	ggagagccct	1380
gttttctatg	tccagacatt	acaagacccc	agcaaaagctc	tgggtcttga	ggagggcaacc	1440
ttgtcatgag	aacagacctg	tcccgggagc	gtcaatgggg	cactggagct	ggagagggaac	1500
gggcatgctt	ctgaggggat	gaccaggcct	agagatgccc	tcggggccaga	ggaagaaggg	1560
aacagagctg	gcccagagtt	gcacaagatc	aacctgggtg	gtccaagggg	gatgatgtta	1620
ggggctctgg	gcaacacggg	gagtggttaa	agcagcctgt	tgtcagccat	cctggaggag	1680
atgcacttgc	tcgaggggctc	ggtgggggtg	cagggaagcc	tggcctatgt	ccccagcag	1740
gcctggatcg	tcagcgggaa	catcaggggag	aacatcctca	tggggaggcg	atatgacaag	1800
gcccagatacc	tccaggtgct	ccactgtctg	tccctgaatc	gggacctgga	actctgtccc	1860
ttttggagaca	tgcacagagt	tggagagcgg	ggcctcaacc	tctctggggg	gcagaacacg	1920
aggatcagcc	tggcccgcgc	cgtctatttc	gaccgtcaaga	tctacctgct	ggacgacccc	1980
ctgtctgtctg	tggagcccca	cgtggggaag	cacatttttg	aggagtgcac	taagaagaca	2040
ctcaggggga	agacggtcgt	cctgggtgacc	caccagctgc	agtacttaga	attttgtggc	2100
cgatcatttt	tgttggaaaa	tgggaaaatc	tgtgaaaatg	gaactcagag	tgagttaagt	2160
cagaaaaagg	ggaaaatagc	ccaacttata	cagaagatgc	acaagggaagc	cactctcgga	2220
atgttgcagg	acacagacaa	gatagcagag	aagccaaagg	tagaaagtc	ggctctggcc	2280
actcctctgg	aagagtctct	caacggaaat	gctgtgccgg	agcactcagc	ccacacggag	2340
gaggagatgg	aagaaggctc	cctgagtttg	agggtctacc	accactacat	ccaggcagct	2400
ggagggtaca	tgtgtctctg	cataattttc	ttcttctgtg	tgtgatcgt	cttcttaacg	2460
atcttcagct	tctggtggct	gagctactgg	tgggagcagg	gctcggggag	caatgacagc	2520
cgagagagca	atggaaacct	ggcagacctg	ggcaacattg	cagacaatcc	tcaactgtcc	2580
tcttaccagc	tgggtgacgg	gctcaacgct	ctctctctca	tctgtgtggg	ggctctgtcc	2640
tcagggtatt	tcaccaaggt	cacgaggaag	gcattccagg	ccctgcacaa	caagctcttc	2700
aacaagggtt	tcgcctgccc	catgagtttc	tttgacacca	tcccataatg	ccggcttttg	2760
aactgcttcg	cagggggact	ggaaacagctg	gaccagctct	tgccctattt	tccagagcag	2820
tctctgtctc	tgtctctaat	ggtgatgcgc	gtcctgttga	ttgtcagttg	gctgtctcca	2880
tatatcctgt	taattgggag	cataatcatg	gttattttgt	tcatttatta	tatgatgttc	2940
aagaaggcca	tcgggtgtgt	caagagactg	gagaactata	gcgggtctcc	tttattctcc	3000
cacatctcca	attctctgca	aggcctgagc	tccatccatg	tctatggaaa	aactgaagac	3060
ttcatcagcc	agttttaagag	gctgactgat	gcgcagaata	actacctgtc	gttggttcta	3120
tcttccacac	gatggatggc	attgaggtcg	gagatcatga	ccaaccttgt	gaccttggct	3180
gttgccctgt	tctgtgcttt	tggcattttc	tcacccccc	actcctttaa	agtcatggct	3240
gtcaacatcg	tgtctcagct	ggcgtccagc	ttccaggcca	ctgcccggat	tggcttggag	3300
acagaggcac	agttccagcc	tgtagagagg	atactgcagt	acatgaagat	gtgtgtctcg	3360
gaagctcctt	tacacatgga	aggcacaagt	tgtccccagg	ggtggccaca	gcattggggaa	3420
atcatatttc	aggattatca	catgaaatc	agagacaaca	cacccaccgt	gcttccagggc	3480
atcaacctga	ccatccggcg	ccacgaagtg	gtgggcatcg	tgggaaggac	gggctctggg	3540
aagtctctct	tgggcatggc	tctcttccgc	ctgggtggagc	ccatggcgagg	ccggattctc	3600
attgacggcg	tggacatttg	cagcatcgcc	ctggaggact	tgcggttccaa	gctctcagtg	3660
atccctcaag	atccagtgct	gctctcagga	accatcagat	tcaacctaga	tcctcttgac	3720
cgctcacact	accagcagat	ctgggagctc	ttggagagga	catctctgac	caaggccatc	3780
tcaaaagtcc	ccaaaaagct	gcatacagat	gtggtggaaa	acgggtggaaa	cttctctgtg	3840
ggggagagag	agctgctctg	cattgccagg	gctgtgcttc	gcaactccaa	gatcatcctt	3900
atcgatgaag	ccacagcctc	cattgacatg	gagacagaca	ccttgatcca	gcgcacaatc	3960
cgtgaagcct	tccaggggctg	caccgtgctc	gtcaattgcc	accgtgtcac	cactgtgtcg	4020
aactgtgacc	acatcctggt	tatgggcaat	gggaagtggtg	tagaatttga	tggccggag	4080
gtactcggga	agaagcctgg	gtcattgttc	gcagccctca	tggccacagc	cacttcttca	4140
ctgagataaa						4149

<210> 18  
 <211> 1379  
 <212> PRT  
 <213> homo sapiens

<400> 18  
 Met Thr Arg Lys Arg Thr Tyr Trp Val Pro Asn Ser Ser Gly Gly Leu

1 5 10 15  
 Val Asn Arg Gly Ile Asp Ile Gly Asp Asp Met Val Ser Gly Leu Ile  
 20 25 30  
 Tyr Lys Thr Tyr Thr Leu Gln Asp Gly Pro Trp Ser Gln Gln Glu Arg  
 35 40 45  
 Asn Pro Glu Ala Pro Gly Arg Ala Ala Val Pro Pro Trp Gly Lys Tyr  
 50 55 60  
 Asp Ala Ala Leu Arg Thr Met Ile Pro Phe Arg Pro Lys Pro Arg Phe  
 65 70 75 80  
 Pro Ala Pro Gln Pro Leu Gly Leu Phe Ser Tyr Leu Thr Val Ser Trp  
 85 90 95  
 Leu Thr Pro Leu Met Ile Gln Ser Leu Arg Ser Arg Leu Asp Glu Asn  
 100 105 110  
 Thr Ile Pro Pro Leu Ser Val His Asp Ala Ser Asp Lys Asn Val Gln  
 115 120 125  
 Arg Leu His Arg Leu Trp Glu Glu Glu Val Ser Arg Arg Gly Ile Glu  
 130 135 140  
 Lys Ala Ser Val Leu Leu Val Met Leu Arg Phe Gln Arg Thr Arg Leu  
 145 150 155 160  
 Ile Phe Asp Ala Leu Leu Gly Ile Cys Phe Cys Ile Ala Ser Val Leu  
 165 170 175  
 Gly Pro Ile Leu Ile Ile Pro Lys Ile Leu Glu Tyr Ser Glu Glu Gln  
 180 185 190  
 Leu Gly Asn Val Val His Gly Val Gly Leu Cys Phe Ala Leu Phe Leu  
 195 200 205  
 Ser Glu Cys Val Lys Ser Leu Ser Phe Ser Ser Ser Trp Ile Ile Asn  
 210 215 220  
 Gln Arg Thr Ala Ile Arg Phe Gln Ala Ala Val Ser Ser Phe Ala Phe  
 225 230 235 240  
 Glu Lys Leu Ile Gln Phe Lys Ser Val Ile His Ile Thr Ser Gly Glu  
 245 250 255  
 Ala Ile Ser Phe Phe Thr Gly Asp Val Asn Tyr Leu Phe Glu Gly Val  
 260 265 270  
 Cys Tyr Gly Pro Leu Val Leu Ile Thr Cys Ala Ser Leu Val Ile Cys  
 275 280 285  
 Ser Ile Ser Ser Tyr Phe Ile Ile Gly Tyr Thr Ala Phe Ile Ala Ile  
 290 295 300  
 Leu Cys Tyr Leu Leu Val Phe Pro Leu Glu Val Phe Met Thr Arg Met  
 305 310 315 320  
 Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser Asp Gln Arg Ile  
 325 330 335  
 Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu Ile Lys Met Tyr  
 340 345 350  
 Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp Leu Arg Arg Lys  
 355 360 365  
 Glu Arg Lys Leu Leu Glu Lys Cys Gly Leu Val Gln Ser Leu Thr Ser  
 370 375 380  
 Ile Thr Leu Phe Ile Ile Pro Thr Val Ala Thr Ala Val Trp Val Leu  
 385 390 395 400  
 Ile His Thr Ser Leu Lys Leu Lys Leu Thr Ala Ser Met Ala Phe Ser  
 405 410 415  
 Met Leu Ala Ser Leu Asn Leu Leu Arg Leu Ser Val Phe Phe Val Pro  
 420 425 430  
 Ile Ala Val Lys Gly Leu Thr Asn Ser Lys Ser Ala Val Met Arg Phe  
 435 440 445  
 Lys Lys Phe Phe Leu Gln Glu Ser Pro Val Phe Tyr Val Gln Thr Leu

450	455	460
Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala Thr Leu Ser Trp		
465	470	475
Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu Glu Leu Glu Arg		480
	485	490
Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg Asp Ala Leu Gly		495
	500	505
Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu His Lys Ile Asn		510
	515	520
Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys Gly Asn Thr Gly		525
	530	535
Ser Gly Lys Ser Ser Leu Ser Ala Ile Leu Glu Glu Met His Leu		540
	545	550
Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala Tyr Val Pro Gln		555
	560	565
Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn Ile Leu Met Gly		570
	580	585
Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu His Cys Cys Ser		590
	595	600
Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp Met Thr Glu Ile		605
	610	615
Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys Gln Arg Ile Ser		620
	625	630
Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr Leu Leu Asp Asp		635
	640	645
Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His Ile Phe Glu Glu		650
	655	660
Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val Leu Val Thr His		665
	670	675
Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile Leu Leu Glu Asn		680
	685	690
Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu Met Gln Lys Lys		695
	700	705
Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys Glu Ala Thr Ser		710
	715	720
Asp Met Leu Gln Asp Thr Ala Lys Ile Ala Glu Lys Pro Lys Val Glu		725
	730	735
Ser Gln Ala Leu Ala Thr Ser Leu Glu Glu Ser Leu Asn Gly Asn Ala		740
	745	750
Val Pro Glu His Gln Leu Thr Gln Glu Glu Glu Met Glu Glu Gly Ser		755
	760	765
Leu Ser Trp Arg Val Tyr His His Tyr Ile Gln Ala Ala Gly Gly Tyr		770
	775	780
Met Val Ser Cys Ile Ile Phe Phe Phe Val Val Leu Ile Val Phe Leu		785
	790	795
Thr Ile Phe Ser Phe Trp Trp Leu Ser Tyr Trp Leu Glu Gln Gly Ser		800
	805	810
Gly Thr Asn Ser Ser Arg Glu Ser Asn Gly Thr Met Ala Asp Leu Gly		815
	820	825
Asn Ile Ala Asp Asn Pro Gln Leu Ser Phe Tyr Gln Leu Val Tyr Gly		830
	835	840
Leu Asn Ala Leu Leu Ile Cys Val Gly Val Cys Ser Ser Gly Ile		845
	850	855
Phe Thr Lys Val Thr Arg Lys Ala Ser Thr Ala Leu His Asn Lys Leu		860
	865	870
Phe Asn Lys Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile Pro		875
	880	885
	890	895



	900		905		910
Ile Gly Arg	Leu Leu Asn Cys Phe Ala Gly Asp	Leu Glu Gln Leu Asp			
915	920	925			
Gln Leu Leu Pro Ile Phe Ser	Glu Gln Phe Leu Val Leu Ser Leu Met				
930	935	940			
Val Ile Ala Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile Leu					
945	950	955			960
Leu Met Gly Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met Met					
965	970	975			
Phe Lys Lys Ala Ile Gly Val Phe Lys Arg Leu Glu Asn Tyr Ser Arg					
980	985	990			
Ser Pro Leu Phe Ser His Ile Leu Asn Ser Leu Gln Gly Leu Ser Ser					
995	1000	1005			
Ile His Val Tyr Gly Lys Thr Glu Asp Phe Ile Ser Gln Phe Lys Arg					
1010	1015	1020			
Leu Thr Asp Ala Gln Asn Asn Tyr Leu Leu Leu Phe Leu Ser Ser Thr					
1025	1030	1035			1040
Arg Trp Met Ala Leu Arg Leu Glu Ile Met Thr Asn Leu Val Thr Leu					
1045	1050	1055			
Ala Val Ala Leu Phe Val Ala Phe Gly Ile Ser Ser Thr Pro Tyr Ser					
1060	1065	1070			
Phe Lys Val Met Ala Val Asn Ile Val Leu Gln Leu Ala Ser Ser Phe					
1075	1080	1085			
Gln Ala Thr Ala Arg Ile Gly Leu Glu Thr Glu Ala Gln Phe Thr Ala					
1090	1095	1100			
Val Glu Arg Ile Leu Gln Tyr Met Lys Met Cys Val Ser Glu Ala Pro					
1105	1110	1115			1120
Leu His Met Glu Gly Thr Ser Cys Pro Gln Gly Trp Pro Gln His Gly					
1125	1130	1135			
Glu Ile Ile Phe Gln Asp Tyr His Met Lys Tyr Arg Asp Asn Thr Pro					
1140	1145	1150			
Thr Val Leu His Gly Ile Asn Leu Thr Ile Arg Gly His Glu Val Val					
1155	1160	1165			
Gly Ile Val Gly Arg Thr Gly Ser Gly Lys Ser Ser Leu Gly Met Ala					
1170	1175	1180			
Leu Phe Arg Leu Val Glu Pro Met Ala Gly Arg Ile Leu Ile Asp Gly					
1185	1190	1195			1200
Val Asp Ile Cys Ser Ile Gly Leu Glu Asp Leu Arg Ser Lys Leu Ser					
1205	1210	1215			
Val Ile Pro Gln Asp Pro Val Leu Leu Ser Gly Thr Ile Arg Phe Asn					
1220	1225	1230			
Leu Asp Pro Phe Asp Arg His Thr Asp Gln Gln Ile Trp Asp Ala Leu					
1235	1240	1245			
Glu Arg Thr Phe Leu Thr Lys Ala Ile Ser Lys Phe Pro Lys Lys Leu					
1250	1255	1260			
His Thr Asp Val Val Glu Asn Gly Gly Asn Phe Ser Val Gly Glu Arg					
1265	1270	1275			1280
Gln Leu Leu Cys Ile Ala Arg Ala Val Leu Arg Asn Ser Lys Ile Ile					
1285	1290	1295			
Leu Ile Asp Glu Ala Thr Ala Ser Ile Asp Met Glu Thr Asp Thr Leu					
1300	1305	1310			
Ile Gln Arg Thr Ile Arg Glu Ala Phe Gln Gly Cys Thr Val Leu Val					
1315	1320	1325			
Ile Ala His Arg Val Thr Thr Val Leu Asn Cys Asp His Ile Leu Val					
1330	1335	1340			
Met Gly Asn Gly Lys Val Val Glu Phe Asp Arg Pro Glu Val Leu Arg					

1345 1350 1355 1360  
 Lys Lys Pro Gly Ser Leu Phe Ala Ala Leu Met Ala Thr Ala Thr Ser  
 1365 1370 1375  
 Ser Leu Arg

<210> 19  
 <211> 2448  
 <212> DNA  
 <213> homo sapiens

<400> 19  
 atgactagga agaggacata ctgggtgccc aactcttctg gtggcctcgt gaatcgtggc 60  
 atcgacatag gcgatgacat ggtttcagga cttatttata aaacctatac tctccaagat 120  
 ggcacctgga gtcagcaaga gagaatccct gaggcctccag ggaggccagc tgtcccaccg 180  
 tgggggaagt atgatgctgc cttgagaacc atgattccct tccgtcccaa gccgaggttt 240  
 cctgcccccc agccccctga caatgctggc ctgtttctct acctaccgt gtcattggctc 300  
 accccgctca tgcacaaag cttaccggagt cgttagatag agaaccacct cctccactg 360  
 tcagtcctat atgcctcaga caaaaatgtc caaaggcttc accgcctttg ggaagaagaa 420  
 gtctcaaggc gagggattga aaaaagcttca gtgcttctgg tgatgctgag gtccagaga 480  
 acaagtttga ttttcgatgc acttctgggc atctgctctt gcattgccag tgactcggg 540  
 ccaattattga ttataccaaa gatcctggaa tattcagaag agcagttggg gaatgtttgc 600  
 catggagtgg gactctgctt tgcccctttt ctctccgaat gtgtgaagtc tctgagtttc 660  
 tctccagtt ggatcatcaa ccaacgcaca gccatcaggt tccagcagc tgtttctctc 720  
 tttgcctttg agaagctcat ccaatttaag ctgttaatac acatcacctc agggagaggcc 780  
 atcagctctct tcaccggtga tgtaaactac ctgtttgaaag ggggtgtgcta tggaccacct 840  
 gtactgacta cctgcgcata gctggctcatc tgcagcattt ctctcactt cattatttga 900  
 tacaactgat ttatttgcac cttatgctat ctctggtttt tcccaactgga ggtattcatg 960  
 acaagaattg ctgtgaaggc tcagcatcac acatctgagg tcacgcacca gccatccgt 1020  
 gtgaccagtg aagtctctac ttcgattaa gctgattaaa tgtacacatg ggagaaacca 1080  
 tttgcaaaaa tcattgaaga cctaagaagg aaggaaaagga agctatttga gaagtgcggg 1140  
 cttgtccaga gcttgacaag tataaccttg ttcatcatcc ccacagtggc cacagcggtc 1200  
 tgggtttctca tccacacatc cttaaagctg aaactcacag cgtcaatggc cttcagcagt 1260  
 ctggcctcct tgaatctctc tcggctgtca gtgttctttg tgcctattgc agtcaaaagt 1320  
 ctacgaatt ccaagtctgc agtgatgagg ttcaagaagt ttttctcca ggagagccct 1380  
 gttttctatg tccagacatg acaagacccc agcaaaagctc tgggtcttga ggaggccacc 1440  
 ttgtctatggc aacagacctg tccgggatac gtcaatgggg cactggagct ggagaggaac 1500  
 gggcatgctt ctgaggggat gaccaggcct agagatgccc tcggggccaga ggaagaaggg 1560  
 aacagccttg gccacagatt gcacaagatc aaacctgggtg tgtccaaggg gatgatgtta 1620  
 ggggtctgcg gcaaacaggg gagtgtgaag agcagcctgt tgtcagccat cctggaggag 1680  
 atgcaattgc tcgagggctc ggtgggggtg cagggaagcc tggcctatgt cccccagcag 1740  
 gcctggatcg tcagcgggaa catcaggggag aacatcceta tgggaggcgc atatgacaag 1800  
 gcccgatacc tccagtgctc ccaactgtgc tccctgaatc ggggaactga actctctccc 1860  
 tttggagaca tgacagagat tggagagcgg ggcctcaacc tctctggggg gcagaaaacag 1920  
 aggatcagcc tggcccgctgc cgtctattcc gaccgtcaga tctacctgct ggacgacccc 1980  
 ctgtctcttg tggacggcca cgtggggaag cacatttttg aggagtgcat taagaagaca 2040  
 ctacggggga agacggtctg cctggtgacc caccagctgc agtacttaga attttgtggc 2100  
 cagatcattt tgttgaaaaa tgggaaaaat tgtgaaaatg gaactcacag tgaatttaag 2160  
 cagaaaaagg ggaatatgac ccaacttata cagaagatgc acaagggaagc cacttcggtt 2220  
 ttcgctgccc ccatgagttt ctttgacacc atccccatag gccggctttt gaactgcttc 2280  
 gcaggggcat tggaaacagct ggaccagctc ttgcccatct ttcacagaca gtctcgtgct 2340  
 ctgtctctaa tggatgacgc cgtctctgtg attgtcagtg tgcgtctctc atatatctgt 2400  
 ttaatgggag ccaataatcat ggttatttgc ttcatttatt atatgtga 2448

<210> 20  
 <211> 812

<212> PRT

<213> homo sapiens

<400> 20

Met Thr Arg Lys Arg Thr Tyr Trp Val Pro Asn Ser Ser Gly Gly Leu  
1 5 10 15  
Val Asn Arg Gly Ile Asp Ile Gly Asp Met Val Ser Gly Leu Ile  
20 25 30  
Tyr Lys Thr Tyr Thr Leu Gln Asp Gly Pro Trp Ser Gln Gln Glu Arg  
35 40 45  
Asn Pro Glu Ala Pro Gly Arg Ala Ala Val Pro Trp Gly Lys Tyr  
50 55 60  
Asp Ala Ala Leu Arg Thr Met Ile Pro Phe Arg Pro Lys Pro Arg Phe  
65 70 75 80  
Pro Ala Pro Gln Pro Leu Gly Leu Phe Ser Tyr Leu Thr Val Ser Trp  
85 90 95  
Leu Thr Pro Leu Met Ile Gln Ser Leu Arg Ser Arg Leu Asp Glu Asn  
100 105 110  
Thr Ile Pro Pro Leu Ser Val His Asp Ala Ser Asp Lys Asn Val Gln  
115 120 125  
Arg Leu His Arg Leu Trp Glu Glu Val Ser Arg Arg Gly Ile Glu  
130 135 140  
Lys Ala Ser Val Leu Leu Val Met Leu Arg Phe Gln Arg Thr Arg Leu  
145 150 155 160  
Ile Phe Asp Ala Leu Leu Gly Ile Cys Phe Cys Ile Ala Ser Val Leu  
165 170 175  
Gly Pro Ile Leu Ile Ile Pro Lys Ile Leu Glu Tyr Ser Glu Glu Gln  
180 185 190  
Leu Gly Asn Val Val His Gly Val Gly Leu Cys Phe Ala Leu Phe Leu  
195 200 205  
Ser Glu Cys Val Lys Ser Leu Ser Phe Ser Ser Ser Trp Ile Ile Asn  
210 215 220  
Gln Arg Thr Ala Ile Arg Phe Gln Ala Ala Val Ser Ser Phe Ala Phe  
225 230 235 240  
Glu Lys Leu Ile Gln Phe Lys Ser Val Ile His Ile Thr Ser Gly Glu  
245 250 255  
Ala Ile Ser Phe Phe Thr Gly Asp Val Asn Tyr Leu Phe Glu Gly Val  
260 265 270  
Cys Tyr Gly Pro Leu Val Leu Ile Thr Cys Ala Ser Leu Val Ile Cys  
275 280 285  
Ser Ile Ser Ser Tyr Phe Ile Ile Gly Tyr Thr Ala Phe Ile Ala Ile  
290 295 300  
Leu Cys Tyr Leu Leu Val Phe Pro Leu Glu Val Phe Met Thr Arg Met  
305 310 315 320  
Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser Asp Gln Arg Ile  
325 330 335  
Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu Ile Lys Met Tyr  
340 345 350  
Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp Leu Arg Arg Lys  
355 360 365  
Glu Arg Lys Leu Leu Glu Lys Cys Gly Leu Val Gln Ser Leu Thr Ser  
370 375 380  
Ile Thr Leu Phe Ile Ile Pro Thr Val Ala Thr Ala Val Trp Val Leu  
385 390 395 400  
Ile His Thr Ser Leu Lys Leu Lys Leu Thr Ala Ser Met Ala Phe Ser  
405 410 415

Met Leu Ala Ser Leu Asn Leu Leu Arg Leu Ser Val Phe Phe Val Pro  
 420 425 430  
 Ile Ala Val Lys Gly Leu Thr Asn Ser Lys Ser Ala Val Met Arg Phe  
 435 440 445  
 Lys Lys Phe Phe Leu Gln Glu Ser Pro Val Phe Tyr Val Gln Thr Leu  
 450 455 460  
 Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala Thr Leu Ser Trp  
 465 470 475 480  
 Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu Glu Leu Glu Arg  
 485 490 495  
 Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg Asp Ala Leu Gly  
 500 505 510  
 Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu His Lys Ile Asn  
 515 520 525  
 Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys Gly Asn Thr Gly  
 530 535 540  
 Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu Glu Met His Leu  
 545 550 555 560  
 Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala Tyr Val Pro Gln  
 565 570 575  
 Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn Ile Leu Met Gly  
 580 585 590  
 Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu His Cys Cys Ser  
 595 600 605  
 Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp Met Thr Glu Ile  
 610 615 620  
 Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys Gln Arg Ile Ser  
 625 630 635 640  
 Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr Leu Leu Asp Asp  
 645 650 655  
 Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His Ile Phe Glu Glu  
 660 665 670  
 Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val Leu Val Thr His  
 675 680 685  
 Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile Leu Leu Glu Asn  
 690 695 700  
 Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu Met Gln Lys Lys  
 705 710 715 720  
 Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys Glu Ala Thr Ser  
 725 730 735  
 Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile Pro Ile Gly Arg  
 740 745 750  
 Leu Leu Asn Cys Phe Ala Gly Asp Leu Glu Gln Leu Asp Gln Leu Leu  
 755 760 765  
 Pro Ile Phe Ser Glu Gln Phe Leu Val Leu Ser Leu Met Val Ile Ala  
 770 775 780  
 Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile Leu Leu Met Gly  
 785 790 795 800  
 Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met  
 805 810

<210> 21  
 <211> 2586  
 <212> DNA  
 <213> homo sapiens

<400> 21

atgactagga	agaggacata	ctgggtgccc	aactcttctg	gtggcctcgt	gaatcgtggc	60
atcgacatag	gcgatgacat	ggtttcagga	cttatttata	aaacctatac	tctccaagat	120
ggccccctgga	gtcagcaaga	gagaaatcct	gaggctccag	ggaggggcagc	tgtccccaccg	180
tgggggaagt	atgatgtctg	cttgagaacc	atgatctcc	tccgtcccaa	cccgaggttt	240
cctgcccccc	agccccctgga	caatgctggc	ctgttctcct	acctcacogt	gtcatggtctc	300
accccgtcta	tgatccaaag	cttacggagt	cgcttagatg	agaacacccat	ccctccactg	360
tcagttccatg	atgcctcaga	caaaaatgtc	caaaggcttc	accgcctttg	gtgagaagaa	420
gtctcaaggc	gagggattga	aaaagcttca	gtgcttctgg	tgatgctgag	gttccagagca	480
acaaaggtga	ttttcgtctg	actctgtggc	atctgctct	gcaattgccag	gtcaggtgtt	540
ccaatatgta	ttataccaaa	gatcctggaa	tattcagaag	agcagttggg	gaatgtgttc	600
catggagtgg	gaactctgtc	tgcctctttt	cttccgaat	gtgtgaagtc	tctgagtttc	660
tctctccagt	ggatcatcaa	ccaacgcaca	gcatcagggt	tccaagcagc	tgtttctctc	720
tttgcccttg	agaagctcat	ccaatttaag	tctgtaatac	acatcacctc	aggagagccc	780
atcagcttct	tcaccggtga	tgtaaacctac	ctgtttgaag	gggtgtgcta	tggaccccta	840
gtactgtaca	cctgtcgcat	gctgtgtcat	tcgacgattt	cttctcactt	cattattgga	900
tacactgcat	ttattgcat	cttatgctat	ctcctgtttt	tcccactgga	ggtattcatg	960
acaagaattg	ctgtgaaggc	tcagcatcac	acatctgagg	tcagcgacca	gcgcattccg	1020
gtgaccagtg	aagttctcac	ttgcattaag	ctgattaaaa	tgtaacacat	ggagaaacca	1080
tttgcacaaa	tcattgaaga	cctaagaagg	aaggaaagga	agctatttga	gaagtgcggg	1140
ctgtgccaga	gcctgacaag	tataaccttg	ttcatcatcc	ccacagtggt	cacagcggtc	1200
tgggttctca	tcacacatct	cttaaagctg	aaactcacag	cgtaaatggc	cttcagcatg	1260
ctggcctcct	tgaatctcct	tcgggtgtca	gtgttcttgg	tgcctattgc	agtcaaaagt	1320
ctcacgaatt	ccaagtctgc	agtgatgagg	ttcaagaagt	ttttctctca	ggagagccct	1380
gttttctatg	tcacagcatt	acaagacccc	agcaaaagct	tggtctttga	ggagaccacc	1440
ttgtcatggc	aacagaccct	tcocggggatc	gtcaatgggg	cactggagct	ggagaggaa	1500
gggcatgctt	ctgaggggat	gaccagggct	agagatgcct	tcggggcaga	ggaagaaggg	1560
aacagcctgg	gccagagatt	gcacaagatc	aaactgtggg	tgtccaaggg	gatgatgtta	1620
ggggtctg	gcacaacggg	gagtggtaag	agcagcctgt	tgtcagccat	cctggaggag	1680
atgcacttgc	tcgagggctc	gggtgggggtg	cagggaaagc	tgccctatgt	ccccagcag	1740
gcctggatgc	tcagcgggaa	catcaggggag	aaactctcca	tgggaggcgc	atatgacaa	1800
gcgcgatacc	tcagggtgct	ccactgtctg	tccttgaaat	gggaccttga	acttctcccc	1860
tttgagagca	tgacagagat	tggagagcgg	ggcctcaacc	tctctggggg	gcagaaacag	1920
aggatocagc	tggcccgccg	cgctctatcc	gaccgtcaga	tctacctgct	ggacgaaccc	1980
ctgtctgctg	tggacgcaca	cggtggggaag	cacatttttg	aggagtgcac	taagaagaca	2040
ctcaggggga	agacggtcgt	cctgtgtgacc	caccagctgc	agtaacttga	atttgtgtgc	2100
cagatcattt	gtgtggaaaa	tgtgaaaaat	tgtgaaaaat	gaactcacag	tgaattaatg	2160
cagaaaaagt	ggaaatatgc	ccaacttctc	cagaagaatgc	acaaggaaagc	cacttcggtt	2220
ttccgctgccc	ccatgagttt	ctttgacacc	atcccaatag	gccggtcttt	gaactgtctc	2280
gcaggggact	tggaaacagct	ggaccagctc	ttgcccatct	tttcagagca	gttctgtgtc	2340
ctgtccttaa	tggtgatcgc	cgctctgttg	attgtcagtg	tgctgtctcc	atatatctgt	2400
ttaatgggag	ccataatcat	gggtatttgc	ttcatttatt	atatgatgtt	caagaagccc	2460
atcgggtgtg	tcaagagact	ggagaactat	agccggtctc	ctttattctc	ccacatctcc	2520
aattctctgc	aaggcctgag	ctccatccat	gtctatggaa	aaactgaaga	cttcacagc	2580
cagtgga						2586

<210> 22  
 <211> 858  
 <212> PRT  
 <213> homo sapiens

<400> 22

Met	Thr	Arg	Lys	Arg	Thr	Tyr	Trp	Val	Pro	Asn	Ser	Ser	Gly	Leu
1				5				10					15	
Val	Asn	Arg	Gly	Ile	Asp	Ile	Gly	Asp	Met	Val	Ser	Gly	Leu	Ile
				20				25				30		

Tyr Lys Thr Tyr Thr Leu Gln Asp Gly Pro Trp Ser Gln Gln Glu Arg  
 35 40 45  
 Asn Pro Glu Ala Pro Gly Arg Ala Ala Val Pro Pro Trp Gly Lys Tyr  
 50 55 60  
 Asp Ala Ala Leu Arg Thr Met Ile Pro Phe Arg Pro Lys Pro Arg Phe  
 65 70 75 80  
 Pro Ala Pro Gln Pro Leu Gly Leu Phe Ser Tyr Leu Thr Val Ser Trp  
 85 90 95  
 Leu Thr Pro Leu Met Ile Gln Ser Leu Arg Ser Arg Leu Asp Glu Asn  
 100 105 110  
 Thr Ile Pro Pro Leu Ser Val His Asp Ala Ser Asp Lys Asn Val Gln  
 115 120 125  
 Arg Leu His Arg Leu Trp Glu Glu Glu Val Ser Arg Arg Gly Ile Glu  
 130 135 140  
 Lys Ala Ser Val Leu Leu Val Met Leu Arg Phe Gln Arg Thr Arg Leu  
 145 150 155 160  
 Ile Phe Asp Ala Leu Leu Gly Ile Cys Phe Cys Ile Ala Ser Val Leu  
 165 170 175  
 Gly Pro Ile Leu Ile Ile Pro Lys Ile Leu Glu Tyr Ser Glu Glu Gln  
 180 185 190  
 Leu Gly Asn Val Val His Gly Val Gly Leu Cys Phe Ala Leu Phe Leu  
 195 200 205  
 Ser Glu Cys Val Lys Ser Leu Ser Phe Ser Ser Ser Trp Ile Ile Asn  
 210 215 220  
 Gln Arg Thr Ala Ile Arg Phe Gln Ala Ala Val Ser Ser Phe Ala Phe  
 225 230 235 240  
 Glu Lys Leu Ile Gln Phe Lys Ser Val Ile His Ile Thr Ser Gly Glu  
 245 250 255  
 Ala Ile Ser Phe Phe Thr Gly Asp Val Asn Tyr Leu Phe Glu Gly Val  
 260 265 270  
 Cys Tyr Gly Pro Leu Val Leu Ile Thr Cys Ala Ser Leu Val Ile Cys  
 275 280 285  
 Ser Ile Ser Ser Tyr Phe Ile Ile Gly Tyr Thr Ala Phe Ile Ala Ile  
 290 295 300  
 Leu Cys Tyr Leu Leu Val Phe Pro Leu Glu Val Phe Met Thr Arg Met  
 305 310 315 320  
 Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser Asp Gln Arg Ile  
 325 330 335  
 Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu Ile Lys Met Tyr  
 340 345 350  
 Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp Leu Arg Arg Lys  
 355 360 365  
 Glu Arg Lys Leu Leu Glu Lys Cys Gly Leu Val Gln Ser Leu Thr Ser  
 370 375 380  
 Ile Thr Leu Phe Ile Ile Pro Thr Val Ala Thr Ala Val Trp Val Leu  
 385 390 395 400  
 Ile His Thr Ser Leu Lys Leu Lys Leu Thr Ala Ser Met Ala Phe Ser  
 405 410 415  
 Met Leu Ala Ser Leu Asn Leu Leu Arg Leu Ser Val Phe Phe Val Pro  
 420 425 430  
 Ile Ala Val Lys Gly Leu Thr Asn Ser Lys Ser Ala Val Met Arg Phe  
 435 440 445  
 Lys Lys Phe Phe Leu Gln Glu Ser Pro Val Phe Tyr Val Gln Thr Leu  
 450 455 460  
 Gln Asp Pro Ser Lys Ala Leu Val Phe Glu Glu Ala Thr Leu Ser Trp  
 465 470 475 480

Gln Gln Thr Cys Pro Gly Ile Val Asn Gly Ala Leu Glu Leu Glu Arg  
 485 490 495  
 Asn Gly His Ala Ser Glu Gly Met Thr Arg Pro Arg Asp Ala Leu Gly  
 500 505 510  
 Pro Glu Glu Glu Gly Asn Ser Leu Gly Pro Glu Leu His Lys Ile Asn  
 515 520 525  
 Leu Val Val Ser Lys Gly Met Met Leu Gly Val Cys Gly Asn Thr Gly  
 530 535 540  
 Ser Gly Lys Ser Ser Leu Leu Ser Ala Ile Leu Glu Glu Met His Leu  
 545 550 555 560  
 Leu Glu Gly Ser Val Gly Val Gln Gly Ser Leu Ala Tyr Val Pro Gln  
 565 570 575  
 Gln Ala Trp Ile Val Ser Gly Asn Ile Arg Glu Asn Ile Leu Met Gly  
 580 585 590  
 Gly Ala Tyr Asp Lys Ala Arg Tyr Leu Gln Val Leu His Cys Cys Ser  
 595 600 605  
 Leu Asn Arg Asp Leu Glu Leu Leu Pro Phe Gly Asp Met Thr Glu Ile  
 610 615 620  
 Gly Glu Arg Gly Leu Asn Leu Ser Gly Gly Gln Lys Gln Arg Ile Ser  
 625 630 635 640  
 Leu Ala Arg Ala Val Tyr Ser Asp Arg Gln Ile Tyr Leu Leu Asp Asp  
 645 650 655  
 Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His Ile Phe Glu Glu  
 660 665 670  
 Cys Ile Lys Lys Thr Leu Arg Gly Lys Thr Val Val Leu Val Thr His  
 675 680 685  
 Gln Leu Gln Tyr Leu Glu Phe Cys Gly Gln Ile Ile Leu Leu Glu Asn  
 690 695 700  
 Gly Lys Ile Cys Glu Asn Gly Thr His Ser Glu Leu Met Gln Lys Lys  
 705 710 715 720  
 Gly Lys Tyr Ala Gln Leu Ile Gln Lys Met His Lys Glu Ala Thr Ser  
 725 730 735  
 Val Phe Arg Cys Pro Met Ser Phe Phe Asp Thr Ile Pro Ile Gly Arg  
 740 745 750  
 Leu Leu Asn Cys Phe Ala Gly Asp Leu Glu Gln Leu Asp Gln Leu Leu  
 755 760 765  
 Pro Ile Phe Ser Glu Gln Phe Leu Val Leu Ser Leu Met Val Ile Ala  
 770 775 780  
 Val Leu Leu Ile Val Ser Val Leu Ser Pro Tyr Ile Leu Leu Met Gly  
 785 790 795 800  
 Ala Ile Ile Met Val Ile Cys Phe Ile Tyr Tyr Met Met Phe Lys Lys  
 805 810 815  
 Ala Ile Gly Val Phe Lys Arg Leu Glu Asn Tyr Ser Arg Ser Pro Leu  
 820 825 830  
 Phe Ser His Ile Leu Asn Ser Leu Gln Gly Leu Ser Ser Ile His Val  
 835 840 845  
 Tyr Gly Lys Thr Glu Asp Phe Ile Ser Gln  
 850 855

<210> 23  
 <211> 3660  
 <212> DNA  
 <213> homo sapiens

<400> 23  
 atgactagga agaggacata ctgggtgccc aactcttctg gtggcctcgt gaatcgctggc

60

atcgacatag	gcgatgacat	ggtttcaggga	cttatttata	aaacctatac	tctccaagat	120
ggccctcgga	gtcagcaaga	gagaaatcct	gaggctccag	ggaggggcagc	tgtcccacccg	180
tgggggaagt	atgatgtctgc	cttgagaacc	atgattccct	tcgtgcccaa	gccgaggttt	240
cctgcccccc	agccctcgga	caatgctggc	ctgttctcct	acctcacctg	gtcatggctc	300
accctcgcta	tgatccaaag	cttacaggagt	cgcttagatg	agaacacatg	ccctccactg	360
tcagtccatg	atgcctcaga	caaaaatgtc	caaaggcttc	accgcctttg	ggaagaagaa	420
gtctcaaggc	gagggttca	aaaagcttca	gtgcttctgg	tgatgtctgag	gttccagaga	480
acaaggttga	ttttcgatgc	acttctgggc	atctgcttct	gcattgccag	tgtactcggg	540
ccaatatgga	ttataccaaa	gatcctggaa	tattcagaag	agcagtgtggg	gaatgttgtc	600
catggagtgg	gactctgctt	tgcccttttt	ctctccgaat	gtgtgaagct	cttgagtttc	660
tcttcacagt	ggaatcatca	ccaacgcaca	gccatcagg	tccaagcagc	tgtttctccc	720
ttgtcctttg	agaagctcat	ccaatttaag	tcgttaatac	acatacctc	aggagagggc	780
atcagctctt	tcaccggtga	tgtaaacatc	ctgtttgaag	gggtgtgcta	tggaccctta	840
gtactgatca	cctgcgcata	gctgggtcat	tgcagcatct	cttctcactt	cattatttga	900
tcacactgat	ttattggcat	cttatgctat	ctcctgggtt	tcaccactgga	ggatattcatg	960
acaagaattg	ctgtgaaggc	tcagcatcac	acatctgagg	tcagcgacca	ggcatccctg	1020
gtgacaggtg	aagtctctac	ttgcattaag	ctgattaaaa	tgtacacatg	cgagaaacca	1080
tttgcaaaaa	tcattgaaga	cctaagaagg	aaggaaagga	agctatttga	gaagtgcggg	1140
ctgtgccaga	gcctgacaa	tataaccttg	tctatcatcc	ccacagtggc	cacagcggtc	1200
tgggtttctca	tcacacatc	cttaaaagctg	aaactcacag	cgctcaatggc	cttcagcagt	1260
ctggcctcct	tgaattctct	tcgggtgtca	gtgttctttg	tgccatttgc	agtcacaaagt	1320
ctcacgaatt	ccaagtctgc	agtgatgagg	ttcaagaagt	ttttctccca	ggtagcgccct	1380
gttttctatg	tcacagcatt	acaagacccc	agcaaaagctc	tggtctttga	ggaggccacc	1440
ttgtcatggc	aacagacctg	tcgggggctc	gtcaatgggg	cactggagct	ggagaggaac	1500
gggcatgctt	ctgaggggat	gaccaggcct	agagatgccc	tcggggccaga	ggagaagaagg	1560
aacagcctgg	gccacagatt	gcacaagatc	aaactgtgtg	tgtccaagtg	gatgacgtta	1620
ggggctctgc	gcacaacggt	gagtggttaag	acagcgcctg	tgtcagccat	cctggaggag	1680
atgactctgc	tcgagggctc	gggtgggggtg	cagggaaagcc	tggcctatgt	ccccagcag	1740
gctcgatgac	tcagcggtgc	catcagggaag	aaactctcca	tgggagggcg	atatgacaag	1800
gcccgatacc	tcagggtgct	ccactgctgc	tcctgaatc	gggacctgga	acttctgccc	1860
tttgagacca	tgacagagat	tggagagcgg	ggcctcaacc	tctctggggg	gcagaacaacg	1920
aggatcagcc	tggcccgctc	cgctatttcc	gaccgtcaga	tctacctgat	ggacgacccc	1980
ctgtctgctg	tggacgcccc	cgtgggggaag	cacatttttg	aggagtgcac	taagaagaca	2040
ctcagggggg	agacgggtgc	cttgggtgacc	caccagctgc	agactttaga	attttgtggc	2100
cagatcattt	tggtggaaaa	tgggaaaaatc	tgtgaaaatg	gaactcacag	tgagttaatg	2160
cagaaaaaag	ggaaaatagc	ccaacttacc	acagaagatg	acaaggaagc	cacttctggt	2220
ttccgctgcc	ccatgagttt	ctttgacacc	atcccaatag	gcgggctttt	gaactgcttc	2280
gcagggggct	tggaaacagct	ggaccagctc	ttgcccatct	tttcagagca	gttcttgctc	2340
ctgtctctaa	tgggtgatgc	cgctcctgtt	attgtcaagt	tgtgtctccc	atatactcgt	2400
ttaatgggag	ccataatcat	ggttatttgc	ttcatttatt	atatgatgtt	caagaaggcc	2460
atcgggtgtg	tcaagagact	ggagaactat	agccggtctc	ctttattctc	ccacatcttc	2520
aattctctgc	aaggcctgag	ctccatccat	gtctatggaa	aaactgaaga	cttcatcagc	2580
cagtttaaga	ggctgactga	tgcgcagaa	aactacctgc	tgttgtttct	atcttccaca	2640
cgatggagtg	cataggcctc	ggagatcatg	accaaccttg	tgaccttgge	tgttgccctg	2700
ttcgtggctt	ttggcatttc	ctccaccccc	tactccttta	aagtcatggc	tgtcaacatc	2760
ctgctcgagc	tggcgtccag	cttcaggccc	actgcocgga	ttggcgttga	gcagagagca	2820
cagtttcacg	ctgtagagag	gatactgcag	tacatgaaga	tgtgtgtctc	ggaagctcct	2880
ttacacatgg	aaggcacaag	ttgtcccccag	gggtggccac	agcatgggga	aatcatattt	2940
caggattatc	acatgaataa	cagagacaac	acaccccacg	tgcttcacgg	cactcaacctg	3000
accatccogc	gccacggaat	gggtgggcatc	gtgggaagga	cgggctctgg	gaagtctctc	3060
ttgggcatgg	ctctcttccg	ctcgttggag	ctcatggcag	ccgggattct	cattgacggc	3120
gtggacattt	gcagcatcgg	cctggaggac	ttgcggtcca	agctctcagt	gatccctcaa	3180
cagctagctg	tgctctcagc	aaacctcaga	ttcaacctag	atcccttga	cgctcacact	3240
gaccagcaga	ctctgggatg	cttggagagg	acattctctga	ccaaggccat	ctcaaaagttc	3300
cccaaaaagc	tgtcatcaga	tgtgtggaaa	aacgggtgaa	acttctctgt	gggggagagg	3360
cagctgctct	gcattgccag	ggctgtgctt	cgcaactcca	agatcatcct	tcgatgaa	3420



gccacagcct ccattgacat ggagacagac accctgatcc agcgacacat cgtgaagcc 3480  
 ttccagggtt gcaccgtgct cgtcattgcc caccgtgtca ccactgtgct gaactgtgac 3540  
 cacatctcgt ttatgggcaa tgggaagggt gtagaatttg atcgcccgga ggtactgcgg 3600  
 aagaagcctg ggtcattggt cgcagccctc atggccacag ccacttcttc actgagataa 3660

<210> 24

<211> 1216

<212> PRT

<213> homo sapiens

<400> 24

Met Thr Arg Lys Arg Thr Tyr Trp Val Pro Asn Ser Ser Gly Gly Leu  
 1 5 10 15  
 Val Asn Arg Gly Ile Asp Ile Gly Asp Asp Met Val Ser Gly Leu Ile  
 20 25 30  
 Tyr Lys Thr Tyr Thr Leu Gln Asp Gly Pro Trp Ser Gln Gln Glu Arg  
 35 40 45  
 Asn Pro Glu Ala Pro Gly Arg Ala Ala Val Pro Pro Trp Gly Lys Tyr  
 50 55 60  
 Asp Ala Ala Leu Arg Thr Met Ile Pro Phe Arg Pro Lys Pro Arg Phe  
 65 70 75 80  
 Pro Ala Pro Gln Pro Leu Gly Leu Phe Ser Tyr Leu Thr Val Ser Trp  
 85 90 95  
 Leu Thr Pro Leu Met Ile Gln Ser Leu Arg Ser Arg Leu Asp Glu Asn  
 100 105 110  
 Thr Ile Pro Pro Leu Ser Val His Asp Ala Ser Asp Lys Asn Val Gln  
 115 120 125  
 Arg Leu His Arg Leu Trp Glu Glu Glu Val Ser Arg Arg Gly Ile Glu  
 130 135 140  
 Lys Ala Ser Val Leu Leu Val Met Leu Arg Phe Gln Arg Thr Arg Leu  
 145 150 155 160  
 Ile Phe Asp Ala Leu Leu Gly Ile Cys Phe Cys Ile Ala Ser Val Leu  
 165 170 175  
 Gly Pro Ile Leu Ile Ile Pro Lys Ile Leu Glu Tyr Ser Glu Gly Gln  
 180 185 190  
 Leu Gly Asn Val Val His Gly Val Gly Leu Cys Phe Ala Leu Phe Leu  
 195 200 205  
 Ser Glu Cys Val Lys Ser Leu Ser Phe Ser Ser Ser Trp Ile Ile Asn  
 210 215 220  
 Gln Arg Thr Ala Ile Arg Phe Gln Ala Ala Val Ser Ser Phe Ala Phe  
 225 230 235 240  
 Glu Lys Leu Ile Gln Phe Lys Ser Val Ile His Ile Thr Ser Gly Glu  
 245 250 255  
 Ala Ile Ser Phe Phe Thr Gly Asp Val Asn Tyr Leu Phe Glu Gly Val  
 260 265 270  
 Cys Tyr Gly Pro Leu Val Leu Ile Thr Cys Ala Ser Leu Val Ile Cys  
 275 280 285  
 Ser Ile Ser Ser Tyr Phe Ile Ile Gly Tyr Thr Ala Phe Ile Ala Ile  
 290 295 300  
 Leu Cys Tyr Leu Leu Val Phe Pro Leu Glu Val Phe Met Thr Arg Met  
 305 310 315 320  
 Ala Val Lys Ala Gln His His Thr Ser Glu Val Ser Asp Gln Arg Ile  
 325 330 335  
 Arg Val Thr Ser Glu Val Leu Thr Cys Ile Lys Leu Ile Lys Met Tyr  
 340 345 350  
 Thr Trp Glu Lys Pro Phe Ala Lys Ile Ile Glu Asp Leu Arg Arg Lys

355										360										365																											
Glu	Arg	Lys	Leu	Leu	Glu	Lys	Cys	Gly	Leu	Val	Gln	Ser	Leu	Thr	Ser	Glu	Arg	Lys	Leu	Leu	Glu	Lys	Cys	Gly	Leu	Val	Gln	Ser	Leu	Thr	Ser	Glu	Arg	Lys	Leu	Leu	Glu	Lys	Cys	Gly	Leu	Val	Gln	Ser	Leu	Thr	Ser
370										375										380																											
Ile	Thr	Leu	Phe	Ile	Ile	Pro	Thr	Val	Ala	Thr	Ala	Val	Trp	Val	Leu	Ile	Thr	Leu	Phe	Ile	Ile	Pro	Thr	Val	Ala	Thr	Ala	Val	Trp	Val	Leu	Ile	Thr	Leu	Phe	Ile	Ile	Pro	Thr	Val	Ala	Thr	Ala	Val	Trp	Val	Leu
385										390										395																											
Ile	His	Thr	Ser	Leu	Lys	Leu	Lys	Leu	Thr	Ala	Ser	Met	Ala	Phe	Ser	Ile	His	Thr	Ser	Leu	Lys	Leu	Lys	Leu	Thr	Ala	Ser	Met	Ala	Phe	Ser	Ile	His	Thr	Ser	Leu	Lys	Leu	Lys	Leu	Thr	Ala	Ser	Met	Ala	Phe	Ser
405										410										415																											
Met	Leu	Ala	Ser	Leu	Asn	Leu	Leu	Arg	Leu	Ser	Val	Phe	Phe	Val	Pro	Met	Leu	Ala	Ser	Leu	Asn	Leu	Leu	Arg	Leu	Ser	Val	Phe	Phe	Val	Pro	Met	Leu	Ala	Ser	Leu	Asn	Leu	Leu	Arg	Leu	Ser	Val	Phe	Phe	Val	Pro
420										425										430																											
Ile	Ala	Val	Lys	Gly	Leu	Thr	Asn	Ser	Lys	Ser	Ala	Val	Met	Arg	Phe	Ile	Ala	Val	Lys	Gly	Leu	Thr	Asn	Ser	Lys	Ser	Ala	Val	Met	Arg	Phe	Ile	Ala	Val	Lys	Gly	Leu	Thr	Asn	Ser	Lys	Ser	Ala	Val	Met	Arg	Phe
435										440										445																											
Lys	Lys	Phe	Phe	Leu	Gln	Glu	Ser	Pro	Val	Phe	Tyr	Val	Gln	Thr	Leu	Lys	Lys	Phe	Phe	Leu	Gln	Glu	Ser	Pro	Val	Phe	Tyr	Val	Gln	Thr	Leu	Lys	Lys	Phe	Phe	Leu	Gln	Glu	Ser	Pro	Val	Phe	Tyr	Val	Gln	Thr	Leu
450										455										460																											
Gln	Asp	Pro	Ser	Lys	Ala	Leu	Val	Phe	Glu	Glu	Ala	Thr	Leu	Ser	Trp	Gln	Asp	Pro	Ser	Lys	Ala	Leu	Val	Phe	Glu	Glu	Ala	Thr	Leu	Ser	Trp	Gln	Asp	Pro	Ser	Lys	Ala	Leu	Val	Phe	Glu	Glu	Ala	Thr	Leu	Ser	Trp
465										470										475																											
Gln	Gln	Thr	Cys	Pro	Gly	Ile	Val	Asn	Gly	Ala	Leu	Glu	Leu	Glu	Arg	Gln	Gln	Thr	Cys	Pro	Gly	Ile	Val	Asn	Gly	Ala	Leu	Glu	Leu	Glu	Arg	Gln	Gln	Thr	Cys	Pro	Gly	Ile	Val	Asn	Gly	Ala	Leu	Glu	Leu	Glu	Arg
485										490										495																											
Asn	Gly	His	Ala	Ser	Glu	Gly	Met	Thr	Arg	Pro	Arg	Asp	Ala	Leu	Gly	Asn	Gly	His	Ala	Ser	Glu	Gly	Met	Thr	Arg	Pro	Arg	Asp	Ala	Leu	Gly	Asn	Gly	His	Ala	Ser	Glu	Gly	Met	Thr	Arg	Pro	Arg	Asp	Ala	Leu	Gly
500										505										510																											
Pro	Glu	Glu	Glu	Gly	Asn	Ser	Leu	Gly	Pro	Glu	Leu	His	Lys	Ile	Asn	Pro	Glu	Glu	Glu	Gly	Asn	Ser	Leu	Gly	Pro	Glu	Leu	His	Lys	Ile	Asn	Pro	Glu	Glu	Glu	Gly	Asn	Ser	Leu	Gly	Pro	Glu	Leu	His	Lys	Ile	Asn
515										520										525																											
Leu	Val	Val	Ser	Lys	Gly	Met	Met	Leu	Gly	Val	Cys	Gly	Asn	Thr	Gly	Leu	Val	Val	Ser	Lys	Gly	Met	Met	Leu	Gly	Val	Cys	Gly	Asn	Thr	Gly	Leu	Val	Val	Ser	Lys	Gly	Met	Met	Leu	Gly	Val	Cys	Gly	Asn	Thr	Gly
530										535										540																											
Ser	Gly	Lys	Ser	Ser	Leu	Leu	Ser	Ala	Ile	Leu	Glu	Glu	Met	His	Leu	Ser	Gly	Lys	Ser	Ser	Leu	Leu	Ser	Ala	Ile	Leu	Glu	Glu	Met	His	Leu	Ser	Gly	Lys	Ser	Ser	Leu	Leu	Ser	Ala	Ile	Leu	Glu	Glu	Met	His	Leu
545										550										555																											
Leu	Glu	Gly	Ser	Val	Gly	Val	Gln	Gly	Ser	Leu	Ala	Tyr	Val	Pro	Gln	Leu	Glu	Gly	Ser	Val	Gly	Val	Gln	Gly	Ser	Leu	Ala	Tyr	Val	Pro	Gln	Leu	Glu	Gly	Ser	Val	Gly	Val	Gln	Gly	Ser	Leu	Ala	Tyr	Val	Pro	Gln
565										570										575																											
Gln	Ala	Trp	Ile	Val	Ser	Gly	Asn	Ile	Arg	Glu	Asn	Ile	Leu	Met	Gly	Gln	Ala	Trp	Ile	Val	Ser	Gly	Asn	Ile	Arg	Glu	Asn	Ile	Leu	Met	Gly	Gln	Ala	Trp	Ile	Val	Ser	Gly	Asn	Ile	Arg	Glu	Asn	Ile	Leu	Met	Gly
580										585										590																											
Gly	Ala	Tyr	Asp	Lys	Ala	Arg	Tyr	Leu	Gln	Val	Leu	His	Cys	Cys	Ser	Gly	Ala	Tyr	Asp	Lys	Ala	Arg	Tyr	Leu	Gln	Val	Leu	His	Cys	Cys	Ser	Gly	Ala	Tyr	Asp	Lys	Ala	Arg	Tyr	Leu	Gln	Val	Leu	His	Cys	Cys	Ser
595										600										605																											
Leu	Asn	Arg	Asp	Leu	Glu	Leu	Leu	Pro	Phe	Gly	Asp	Met	Thr	Glu	Ile	Leu	Asn	Arg	Asp	Leu	Glu	Leu	Leu	Pro	Phe	Gly	Asp	Met	Thr	Glu	Ile	Leu	Asn	Arg	Asp	Leu	Glu	Leu	Leu	Pro	Phe	Gly	Asp	Met	Thr	Glu	Ile
610										615										620																											
Gly	Glu	Arg	Gly	Leu	Asn	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ser	Gly	Glu	Arg	Gly	Leu	Asn	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ser	Gly	Glu	Arg	Gly	Leu	Asn	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ser
625										630										635																											
Leu	Ala	Arg	Ala	Val	Tyr	Ser	Asp	Arg	Gln	Ile	Tyr	Leu	Leu	Asp	Asp	Leu	Ala	Arg	Ala	Val	Tyr	Ser	Asp	Arg	Gln	Ile	Tyr	Leu	Leu	Asp	Asp	Leu	Ala	Arg	Ala	Val	Tyr	Ser	Asp	Arg	Gln	Ile	Tyr	Leu	Leu	Asp	Asp
645										650										655																											
Pro	Leu	Ser	Ala	Val	Asp	Ala	His	Val	Gly	Lys	His	Ile	Phe	Glu	Glu	Pro	Leu	Ser	Ala	Val	Asp	Ala	His	Val	Gly	Lys	His	Ile	Phe	Glu	Glu	Pro	Leu	Ser	Ala	Val	Asp	Ala	His	Val	Gly	Lys	His	Ile	Phe	Glu	Glu
660										665										670																											
Cys	Ile	Lys	Lys	Thr	Leu	Arg	Gly	Lys	Thr	Val	Val	Leu	Val	Thr	His	Cys	Ile	Lys	Lys	Thr	Leu	Arg	Gly	Lys	Thr	Val	Val	Leu	Val	Thr	His	Cys	Ile	Lys	Lys	Thr	Leu	Arg	Gly	Lys	Thr	Val	Val	Leu	Val	Thr	His
675										680										685																											
Gln	Leu	Gln	Tyr	Leu	Glu	Phe	Cys	Gly	Gln	Ile	Ile	Leu	Leu	Glu	Asn	Gln	Leu	Gln	Tyr	Leu	Glu	Phe	Cys	Gly	Gln	Ile	Ile	Leu	Leu	Glu	Asn	Gln	Leu	Gln	Tyr	Leu	Glu	Phe	Cys	Gly	Gln	Ile	Ile	Leu	Leu	Glu	Asn
690										695										700																											
Gly	Lys	Ile	Cys	Glu	Asn	Gly	Thr	His	Ser	Glu	Leu	Met	Gln	Lys	Lys	Gly	Lys	Ile	Cys	Glu	Asn	Gly	Thr	His	Ser	Glu	Leu	Met	Gln	Lys	Lys	Gly	Lys	Ile	Cys	Glu	Asn	Gly	Thr	His	Ser	Glu	Leu	Met	Gln	Lys	Lys
705										710										715																											
Gly	Lys	Tyr	Ala	Gln	Leu	Ile	Gln	Lys	Met	His	Lys	Glu	Ala	Thr	Ser	Gly	Lys	Tyr	Ala	Gln	Leu	Ile	Gln	Lys	Met	His	Lys	Glu	Ala	Thr	Ser	Gly	Lys	Tyr	Ala	Gln	Leu	Ile	Gln	Lys	Met	His	Lys	Glu	Ala	Thr	Ser
725										730										735																											
Val	Phe	Arg	Cys	Pro	Met	Ser	Phe	Phe	Asp	Thr	Ile	Pro	Ile	Gly	Arg	Val	Phe	Arg	Cys	Pro	Met	Ser	Phe	Phe	Asp	Thr	Ile	Pro	Ile	Gly	Arg	Val	Phe	Arg	Cys	Pro	Met	Ser	Phe	Phe	Asp	Thr	Ile	Pro	Ile	Gly	Arg
740										745										750																											
Leu	Leu	Asn	Cys	Phe	Ala	Gly	Asp	Leu	Glu	Gln	Leu	Asp	Gln	Leu	Leu	Leu	Leu	Asn	Cys	Phe	Ala	Gly	Asp	Leu	Glu	Gln	Leu	Asp	Gln	Leu	Leu	Leu	Leu	Asn	Cys	Phe	Ala	Gly	Asp	Leu	Glu	Gln	Leu	Asp	Gln	Leu	Leu
755										760										765																											
Pro	Ile	Phe	Ser	Glu	Gln	Phe	Leu	Val	Leu	Ser	Leu	Met	Val	Ile	Ala	Pro	Ile	Phe	Ser	Glu	Gln	Phe	Leu	Val	Leu	Ser	Leu	Met	Val	Ile	Ala	Pro	Ile	Phe	Ser	Glu	Gln	Phe	Leu	Val	Leu	Ser	Leu	Met	Val	Ile	Ala
770										775										780																											
Val	Leu	Leu	Ile	Val	Ser	Val	Leu	Ser	Pro	Tyr	Ile	Leu	Leu	Met	Gly	Val	Leu	Leu	Ile	Val	Ser	Val	Leu	Ser	Pro	Tyr	Ile	Leu	Leu	Met	Gly	Val	Leu	Leu	Ile	Val	Ser	Val	Leu	Ser	Pro	Tyr	Ile	Leu	Leu	Met	Gly
785										790										795																											
Ala	Ile	Ile	Met	Val	Ile	Cys	Phe	Ile	Tyr	Tyr	Met	Met	Phe	Lys	Lys	Ala	Ile	Ile	Met	Val	Ile	Cys	Phe	Ile	Tyr	Tyr	Met	Met	Phe	Lys	Lys	Ala	Ile	Ile	Met	Val	Ile	Cys	Phe	Ile	Tyr	Tyr	Met	Met	Phe	Lys	Lys

					805					810						815
Ala	Ile	Gly	Val	Phe	Lys	Arg	Leu	Glu	Asn	Tyr	Ser	Arg	Ser	Pro	Leu	
					820											
Phe	Ser	His	Ile	Leu	Asn	Ser	Leu	Gln	Gly	Leu	Ser	Ser	Ile	His	Val	
					835											
Tyr	Gly	Lys	Thr	Glu	Asp	Phe	Ile	Ser	Gln	Phe	Lys	Arg	Leu	Thr	Asp	
					850											
Ala	Gln	Asn	Asn	Tyr	Leu	Leu	Leu	Phe	Leu	Ser	Ser	Thr	Arg	Trp	Met	
					865											
Ala	Leu	Arg	Leu	Glu	Ile	Met	Thr	Asn	Leu	Val	Thr	Leu	Ala	Val	Ala	
					885											
Leu	Phe	Val	Ala	Phe	Gly	Ile	Ser	Ser	Thr	Pro	Tyr	Ser	Phe	Lys	Val	
					900											
Met	Ala	Val	Asn	Ile	Val	Leu	Gln	Leu	Ala	Ser	Ser	Phe	Gln	Ala	Thr	
					915											
Ala	Arg	Ile	Gly	Leu	Glu	Thr	Glu	Ala	Gln	Phe	Thr	Ala	Val	Glu	Arg	
					930											
Ile	Leu	Gln	Tyr	Met	Lys	Met	Cys	Val	Ser	Glu	Ala	Pro	Leu	His	Met	
					945											
Glu	Gly	Thr	Ser	Cys	Pro	Gln	Gly	Trp	Pro	Gln	His	Gly	Glu	Ile	Ile	
					965											
Phe	Gln	Asp	Tyr	His	Met	Lys	Tyr	Arg	Asp	Asn	Thr	Pro	Thr	Val	Leu	
					980											
His	Gly	Ile	Asn	Leu	Thr	Ile	Arg	Gly	His	Glu	Val	Val	Gly	Ile	Val	
					995											
Gly	Arg	Thr	Gly	Ser	Gly	Lys	Ser	Ser	Leu	Gly	Met	Ala	Leu	Phe	Arg	
					1010											
Leu	Val	Glu	Pro	Met	Ala	Gly	Arg	Ile	Leu	Ile	Asp	Gly	Val	Asp	Ile	
					1025											
Cys	Ser	Ile	Gly	Leu	Glu	Asp	Leu	Arg	Ser	Lys	Leu	Ser	Val	Ile	Pro	
					1045											
Gln	Asp	Pro	Val	Leu	Leu	Ser	Gly	Thr	Ile	Arg	Phe	Asn	Leu	Asp	Pro	
					1060											
Phe	Asp	Arg	His	Thr	Asp	Gln	Gln	Ile	Trp	Asp	Ala	Leu	Glu	Arg	Thr	
					1075											
Phe	Leu	Thr	Lys	Ala	Ile	Ser	Lys	Phe	Pro	Lys	Lys	Leu	His	Thr	Asp	
					1090											
Val	Val	Glu	Asn	Gly	Gly	Asn	Phe	Ser	Val	Gly	Glu	Arg	Gln	Leu	Leu	
					1105											
Cys	Ile	Ala	Arg	Ala	Val	Leu	Arg	Asn	Ser	Lys	Ile	Ile	Leu	Ile	Asp	
					1125											
Glu	Ala	Thr	Ala	Ser	Ile	Asp	Met	Glu	Thr	Asp	Thr	Leu	Ile	Gln	Arg	
					1140											
Thr	Ile	Arg	Glu	Ala	Phe	Gln	Gly	Cys	Thr	Val	Leu	Val	Ile	Ala	His	
					1155											
Arg	Val	Thr	Thr	Val	Leu	Asn	Cys	Asp	His	Ile	Leu	Val	Met	Gly	Asn	
					1170											
Gly	Lys	Val	Val	Glu	Phe	Asp	Arg	Pro	Glu	Val	Leu	Arg	Lys	Lys	Pro	
					1185											
Gly	Ser	Leu	Phe	Ala	Ala	Leu	Met	Ala	Thr	Ala	Thr	Ser	Ser	Leu	Arg	
					1205											

<210> 25  
 <211> 5020  
 <212> DNA  
 <213> homo sapiens

<400> 25

agagacagga	acagagcccc	tcatctcacc	tctgggctac	catacagaaa	agcagggtga	60
tttgaataaa	ccaggttggc	aaatcatact	atagctgaaa	gaattggcag	gaactgaaaa	120
tgcatagaaa	gaggacatac	tgggtgccca	actcttctgg	tgccctcgtg	aatcgtggca	180
tcgacatagg	cgatgacatg	gtttcaggac	ttatttataa	aaactatact	ctccaagatg	240
gccctcggag	tcagcaagag	agaaatcctg	aggctccagg	gagggcagct	gtcccaccgt	300
gggggaagta	tgatgctgoc	ttgagaacca	tgattccctt	ccgtcccaag	ccgaggtttc	360
ctgcccccca	gcccctggac	aatgctggcg	tgttctccta	ctccaccgtg	tcattggctca	420
cccgcgtcat	gatacaaaag	ttacggagtc	gcttagatga	gaacaccact	ccctccactgt	480
cagtcacatg	tgcttcacag	aaaaatgtcc	aaaggcttca	ccgcctttgg	gaaggaagag	540
tctcaaggcg	agggatgtaa	aaagcttcag	tgcttctggt	gatgctgagg	ttccagagaa	600
caaggctgat	ttctgatgca	ctctcgggca	tctgtctctg	cattgccagt	gtactcgggc	660
cagactgcac	caatggggga	ggtgggagtc	ttcccagaag	aaaactgagg	cactgggtacc	720
agctacgggg	aggtgaagat	attgattata	ccaaagatcc	tggaatatcc	agaagagcag	780
ttggggaaatg	ttgtccatgg	agtgggactc	tgctttggcc	ttttctctct	cgaatgtgtg	840
aagtctctga	gtttctctct	cagttgggac	atcaaccaac	gcacagccat	caggttccaa	900
gcagctgttt	ctctctttgc	ctttgagaag	ctcatccaat	ttaagcttgt	aatcacatc	960
agctcaggag	aggccatcag	cttcttcacc	ggtgatgtaa	actacctgtt	tgaagggtgtg	1020
tgctatggac	ccctagtact	gatcacctgc	gcactcgtgg	tcactctgcag	cattttctcc	1080
tacttctatta	ttggatacac	tgcatattat	gccattctat	gctatctctc	ggttttccca	1140
ctggaggttat	tcattgacaa	aatggctgtg	aaggctcagc	atcacacatc	tgagggtcagc	1200
gaccacggca	tcctgtgtac	cagtgaaagt	ctcaactgtca	ttaagctgat	taaaagtac	1260
acatggggaga	aaccatttgc	aaaaatcatt	gaagacctaa	gaaggaagga	aaggaagcta	1320
ttgggaagat	gcgggcttgt	ccagagcctg	acaagtataa	ccctgttcat	catcccccac	1380
gtggccacag	cgggtctggg	tctcatccac	acatccttaa	agctgaaact	cacagcggtca	1440
atggccttca	gcatgctggc	ctccttgaat	ctccttcggc	tgctcagttg	ctttgtgcct	1500
attgcagtca	aaggtctcac	gaattccaa	ttcgcagtga	tgaggttcaa	gaagtttttc	1560
ctccaggaga	gcctcttttt	ctatgtccag	acattcaaac	accccagcaa	agctctggct	1620
tttggaggag	ccacctgttc	atggcaaac	acactgtccc	ggatcgtcaa	tgggggcactg	1680
gagctggaga	ggaacgggca	tgctctctag	gggatgcaca	ggcctagaga	tgcccctggg	1740
ccagaggaag	aagggaaacg	cctggggcca	gagttgcaca	agatcaacct	gggtggtgtcc	1800
aaggggatga	tgtttagggg	ctgcggcaac	acggggagtg	gtaagagcag	ctcgtttgtca	1860
gccatctctg	aggagatgca	cttgctccag	ggctcgggtg	gggtgcaggg	aagcctggcc	1920
tatgtccccc	agcaggcctg	gatcgtccag	gggaacatca	gggagaacat	cactctggga	1980
ggcccatatg	acaaggcccc	atacctccag	gtgctccaat	gctgctccct	gaatcgggag	2040
ctggaaactc	tgcccctttg	agacatgaca	gagattggag	agcgggggct	caacctctct	2100
ggggggcaga	aacagaggat	cagcctggcc	cgcccgctct	attccgaccg	tcagatctac	2160
ctgctggagc	accccctgtc	tgcttgggac	gcccacgtgg	ggaagcacat	ttttgaggag	2220
tgcatataga	agacactcag	ggggaagacg	tgctgtctgg	tgaccaccca	gctgcagtag	2280
ttagaatttt	tggtgccagat	cattttgttg	gaaaatggga	aaatctgtga	aaatgggaact	2340
ccagctgagt	taatgcagaa	aaaggggaaa	tatgcccac	ttatccagaa	gatgcacaa	2400
gaagccactt	cggacatgtt	gcaggacaca	gcaaagatag	cagagaagcc	aaaggtagaa	2460
atgcaggctc	tggccacctc	ccctgaaagag	tctctcaacg	gaaatgctgt	gcgggagcat	2520
cagctcacac	aggaggagga	gattgaaagaa	ggctccctga	gttggagggt	ctaccaaccat	2580
tacatccagg	cagctggagg	ttacatggtc	tcttgcataa	ttttctctct	cggtggtcgtg	2640
atcgtctctt	taacagatct	cagcttctgg	tggtcagct	actggttgga	gcagggtcgt	2700
gggaccaata	gcagcccgaga	gagcaatgga	accatggcag	acctggggca	cattgcagac	2760
aatcctcaac	tgctcttcta	ccagctgggt	tacgggctca	acgcctctgt	ctctactctg	2820
gtgggggtct	gctcctcagg	gattttcacc	aaggtcacga	ggaaggcact	cagccgctct	2880
cacaaacagg	tcttcaacaa	ggttttccgc	tgccccatga	gtttcttttg	caccatccca	2940
ataggccgct	ttttgaactg	ctctgcaggg	gaacttggaa	agctggacca	gctcttgcgc	3000
atcttctctg	agcagttctc	ggtcctgtcc	ttaatggtga	tcgcgctctc	gttgattgtc	3060
agtgctctgt	ctccatatat	cctgtttaat	ggagccataa	tcattggttat	ttgcttcat	3120
tattatatgt	gagttaggttc	tttttgcctg	tgactttggg	agcaagggct	gggacaaacc	3180
cagactagat	ggtcccacag	gtggacggct	caggttccct	acctccactg	tcctatcgag	3240
atgtttcaaga	aggccatcgg	tggtttcaag	agactggaga	actatagccg	actcttttta	3300

tctccca	tctccaattc	tctgcaagcg	ctgagctcca	tccatgtcta	tggaaaaact	3360
gaagacttca	tcagccagtg	agtccttctg	ctgccatttt	gagaatgatg	gaaccaccag	3420
gggtgggtgg	ggagccaggg	aaagaatggg	acgtcttgag	agtggatcat	cttcaaaaag	3480
cattcagaga	gccacattgg	tcgattgaga	cgtattctct	gagccttcca	gaacctgtcg	3540
gaaccattct	ttcatttaag	aggctgactg	atgcgcagaa	taactacctg	ctgttgtttc	3600
tatcttccac	acgatggatg	gcattgagcg	tggagatcat	gaccaacctt	gtgaccttgg	3660
ctgttgccct	gttcgtggct	tttggcattt	cctccacccc	ctactccttt	aaagtcatgg	3720
ctgtcaacat	cgtgctgcag	ctggcgtcca	gcttccaggg	cactgcccg	attggcttgg	3780
agacagagcg	acagtccacg	gctgtagaga	ggatactgca	gtacatgaag	atgtgtgtct	3840
cggaaagctc	tttacacatg	gaaggcacia	gtgtcccca	gggtgggcca	cagcatgggg	3900
aaatcatatt	tcaggattat	cacatgaat	acagagacaa	cacaccacc	gtcttccag	3960
gcatacaact	gaccatccgc	ggccacgaag	tgtggggcat	cgtgggaagg	acgggctctg	4020
ggaagtccct	cttgggcatg	gctctcttcc	gcctgggtgga	gcccatggca	ggccggatcc	4080
tcattgacgg	cgtggacatt	tgcagcatcg	gcctggagga	cttgcgggtcc	aagctctcag	4140
tgatccctca	agatccagtg	ctgctctcag	gaaccatcag	attcaacctc	gatcccttgg	4200
accgtcacac	tgaccagcag	atctgggatg	ccttggagag	gacattctcg	accaaggcca	4260
tctcaaaagt	ccccaaaaag	ctgcatacag	atgtggtgga	aaacggtgga	aacttctctg	4320
tgggggagag	gcagctgctc	tgcattgcca	gggctgtgct	tcgcacctcc	aagatcatcc	4380
ttatcgatga	agccacagcc	tccattgaca	tggagacaga	cacctgtatc	cagcgacaaa	4440
tccgtgaagc	cttccagggc	tgcaccgtgc	tcgtcatg	ccaccgtgtc	accactgtgc	4500
tgaactgtga	ccacatctct	gttatgggca	atgggaaggt	ggtagaattt	gatcgggcgg	4560
aggctactcg	gaagaagcct	gggtcattgt	tcgcagccct	catggccaca	gccacttctt	4620
cactgagata	aggagatgtg	gagacttcat	ggagctggcg	agctgagctc	agaggttcac	4680
acaggtgcag	cttcgagggc	cacagtctgc	gaccttcttg	tttggagatg	agaacttctc	4740
ctggaagcag	gggtaaatgt	aggggggggtg	gggatttgctg	gatggaaacc	ctgggaatagg	4800
ctacttggatg	gctctcaaga	ccttagaacc	ccagaacatc	ctaagacatg	ggattcagtg	4860
atcatgtgtg	tctcttttta	acttacatgc	tgaataattt	tataataagg	taaaagctta	4920
tagtttctg	atctgtgtta	gaagtgttgc	aaatgctgta	ctgactttgt	aaaaataaaa	4980
actaaggaaa	actcaaaaaa	aaaaaaaaaa	aaaaaaaaaa			5020